



C:\stnweb\Queries\4.str



chain nodes :

1 2 3 4 15 16 24 25

ring nodes :

10 11 12 13 14 17 18 19 20 21

chain bonds :

13-15 15-16 16-17 18-24 20-25

ring bonds :

10-14 11-12 12-13 13-14 17-18 17-21 18-19 19-20 20-21

exact/norm bonds :

10-14 11-12 12-13 13-14 13-15 15-16 16-17 17-18 17-21 18-19 18-24 19-20 20-21
20-25

isolated ring systems :

containing 10 : 17 :



G1:[*1],[*2],[*3],[*4]

G2:S,N

G3:O,S

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom
16:CLASS 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 24:CLASS 25:CLASS



chain nodes :

1 2 3 4 12 13 21 22

ring nodes :

10 11 14 15 16 17 18 24 26 27 28

chain bonds :

11-12 12-13 13-14 15-21 17-22

ring bonds :

10-24 14-15 14-18 15-16 16-17 17-18 24-27 26-27 26-28

exact/norm bonds :

10-24 11-12 12-13 13-14 14-15 14-18 15-16 15-21 16-17 17-18 17-22 24-27 26-27 26-28

isolated ring systems :

containing 14 :



G1:[*1],[*2],[*3],[*4]

G2:S,N

G3:O,S

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 10:Atom 11:Atom 12:Atom 13:CLASS 14:Atom 15:Atom
16:Atom 17:Atom 18:Atom 21:CLASS 22:CLASS 24:Atom 26:Atom 27:Atom 28:Atom



chain nodes :

1 2 3 4 12 13 21 22

ring nodes :

10 11 14 15 16 17 18 24 26 27 28

chain bonds :

11-12 12-13 13-14 15-21 17-22

ring bonds :

14-15 14-18 15-16 16-17 17-18

exact/norm bonds :

11-12 12-13 13-14 14-15 14-18 15-16 15-21 16-17 17-18 17-22

isolated ring systems :

containing 14 :

G1:[*1],[*2],[*3],[*4]


G2:S,N

G3:O,S

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 10:Atom 11:Atom 12:Atom 13:CLASS 14:Atom 15:Atom
16:Atom 17:Atom 18:Atom 21:CLASS 22:CLASS 24:Atom 26:Atom 27:Atom 28:Atom

c:\stnweb\Queries\3.str



chain nodes :

1 2 3 4 12 13 21 22

ring nodes :

10 11 14 15 16 17 18 24 26 27 28

chain bonds :

12-13 13-14 15-21 17-22

ring bonds :

14-15 14-18 15-16 16-17 17-18

exact/norm bonds :

12-13 13-14 14-15 14-18 15-16 15-21 16-17 17-18 17-22

isolated ring systems :

containing 14 :



G1:[*1],[*2],[*3],[*4]

G2:S,N

G3:O,S

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 10:Atom 11:Atom 12:Atom 13:CLASS 14:Atom 15:Atom
16:Atom 17:Atom 18:Atom 21:CLASS 22:CLASS 24:Atom 26:Atom 27:Atom 28:Atom



chain nodes :

1 2 3 4 12 13 20 21

ring nodes :

10 11 14 15 16 17 18 23 25 26 27

chain bonds :

12-13 13-14 15-20 17-21

ring bonds :

14-15 14-18 15-16 16-17 17-18

exact/norm bonds :

12-13 13-14 15-16 15-20 16-17 17-21

exact bonds :

14-15 14-18 17-18

isolated ring systems :

containing 14 :



G1:[*1],[*2],[*3],[*4]

G3:0,s

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 10:Atom 11:Atom 12:Atom 13:CLASS 14:Atom 15:Atom
16:Atom 17:Atom 18:Atom 20:CLASS 21:CLASS 23:Atom 25:Atom 26:Atom 27:Atom

C:\stnweb\Queries\9.str



chain nodes :

1 2 9 10 12

ring nodes :

3 4 5 6 7

chain bonds :

1-2 2-12 3-12 4-9 6-10

ring bonds :

3-7 3-4 4-5 5-6 6-7

exact/norm bonds :

1-2 2-12 3-7 3-12 4-5 4-9 5-6 6-7 6-10

exact bonds :

3-4

isolated ring systems :



containing 3 :

G1:0,5

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 9:CLASS 10:CLASS 12:CLASS

C:\stnweb\queries\6.str



chain nodes :
 1 2 9 10 12 14 15 16 17 23 24 25 26 27
 ring nodes :
 3 4 5 6 7
 chain bonds :
 1-2 2-12 3-12 4-9 6-10
 ring bonds :
 3-7 3-4 4-5 5-6 6-7
 exact/norm bonds :
 1-2 2-12 3-7 3-12 4-5 4-9 5-6 6-7 6-10
 exact bonds :
 3-4
 isolated ring systems :
 containing 3 :


G1:O,S

G2:[*1],[*2],[*3],[*4]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 9:CLASS 10:CLASS 12:CLASS
 14:CLASS 15:CLASS 16:CLASS 17:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS

C:\stnweb\Queries\6.str



chain nodes :

1 2 9 10 12 14 15 16 17

ring nodes :

3 4 5 6 7 23 24 25 26 27

chain bonds :

1-2 2-12 3-12 4-9 6-10

ring bonds :

3-7 3-4 4-5 5-6 6-7 23-24 23-27 24-25 25-26

exact/norm bonds :

1-2 2-12 3-7 3-12 4-5 4-9 5-6 6-7 6-10 23-24 23-27 24-25 25-26

exact bonds :

3-4

isolated ring systems :



containing 3 :

G1:O,S

G2:[*1],[*2],[*3],[*4]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 9:CLASS 10:CLASS 12:CLASS
14:CLASS 15:CLASS 16:CLASS 17:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS



chain nodes :

2 9 10 12 14 15 16 17

ring nodes :

1 3 4 5 6 7 23 24 25 26 27

chain bonds :

1-2 2-12 3-12 4-9 6-10

ring bonds :

1-27 3-7 3-4 4-5 5-6 6-7 23-24 23-27 24-25 25-26

exact/norm bonds :

1-2 1-27 2-12 3-7 3-12 4-5 4-9 5-6 6-7 6-10 23-24 23-27 24-25 25-26

exact bonds :

3-4

isolated ring systems :



containing 3 :

G1:O,S

G2:[*1],[*2],[*3],[*4]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 9:CLASS 10:CLASS 12:CLASS
14:CLASS 15:CLASS 16:CLASS 17:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS



chain nodes :

1 8 9 11 13 14 15 16

ring nodes :

2 3 4 5 6 22 23 24 25 26 27

chain bonds :

1-11 2-11 3-8 5-9 26-27

ring bonds :

2-6 2-3 3-4 4-5 5-6 22-23 22-26 23-24 24-25

exact/norm bonds :

1-11 2-6 2-11 3-4 3-8 4-5 5-6 5-9 22-23 22-26 23-24 24-25 26-27

exact bonds :

2-3

isolated ring systems :



containing 2 :

G1:O,S

G2:[*1],[*2],[*3],[*4]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS 9:CLASS 11:CLASS 13:CLASS
14:CLASS 15:CLASS 16:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:Atom



chain nodes :

1 8 9 11 13 14 15 16

ring nodes :

2 3 4 5 6 22 23 24 25 26 27

chain bonds :

1-11 2-11 3-8 5-9 26-27

ring bonds :

2-6 2-3 3-4 4-5 5-6 22-23 22-26 23-24 24-25

exact/norm bonds :

1-11 2-6 2-11 3-4 3-8 4-5 5-6 5-9 22-23 22-26 23-24 24-25 26-27

exact bonds :

2-3

isolated ring systems :



containing 2 :

G1:O,s

G2:[*1],[*2],[*3],[*4]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS 9:CLASS 11:CLASS 13:CLASS
14:CLASS 15:CLASS 16:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:Atom



chain nodes :

1 2 4 5 59 74

ring nodes :

6	7	8	9	10	11	12	13	14	15	19	20	21	22	23	24	25	26	27	28	29	30	31
32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	60	
61	62	63	64	65	66	67	68	69	70													

chain bonds :

1-2 2-4 2-5 5-59

ring bonds :

6-7	6-11	7-8	8-9	9-10	10-11	10-12	11-15	12-13	13-14	14-15	19-20	19-24	20-21
21-22	22-23	23-24	25-26	25-30	26-27	27-28	28-29	29-30	29-31	30-33	31-32	32-33	32-33
34-35	34-39	35-36	36-37	37-38	38-39	38-40	39-42	40-41	41-42	43-44	43-48	44-45	
45-46	46-47	47-48	47-49	48-52	49-50	50-51	51-52	60-61	60-65	61-62	62-63	63-64	
64-65	66-67	66-70	67-68	68-69	69-70								

exact/norm bonds :

1-2	2-4	2-5	5-59	6-7	6-11	7-8	8-9	9-10	10-11	10-12	11-15	12-13	13-14	14-15
29-30	29-31	30-33	31-32	32-33	38-39	38-40	39-42	40-41	41-42	66-67	66-70	67-68		
68-69	69-70													

exact bonds :

25-26	25-30	26-27	27-28	28-29	34-35	34-39	35-36	36-37	37-38	47-49	48-52	49-50
50-51	51-52											

normalized bonds :

19-20	19-24	20-21	21-22	22-23	23-24	43-44	43-48	44-45	45-46	46-47	47-48	60-61
60-65	61-62	62-63	63-64	64-65								

isolated ring systems :

containing 25 : 34 : 43 : 60 : 66 :



G1:0,5

G2:[*1],[*2],[*3],[*4]

G3:[*1],[*2],[*3],[*4],[*5],[*6]

Match level :

1:CLASS	2:CLASS	4:CLASS	5:CLASS	6:Atom	7:Atom	8:Atom	9:Atom	10:Atom	11:Atom
12:Atom	13:Atom	14:Atom	15:Atom	18:CLASS	19:Atom	20:Atom	21:Atom	22:Atom	23:Atom
24:Atom	25:Atom	26:Atom	27:Atom	28:Atom	29:Atom	30:Atom	31:Atom	32:Atom	33:Atom
34:Atom	35:Atom	36:Atom	37:Atom	38:Atom	39:Atom	40:Atom	41:Atom	42:Atom	43:Atom
44:Atom	45:Atom	46:Atom	47:Atom	48:Atom	49:Atom	50:Atom	51:Atom	52:Atom	59:CLASS
60:Atom	61:Atom	62:Atom	63:Atom	64:Atom	65:Atom	66:Atom	67:Atom	68:Atom	69:Atom
70:Atom	74:CLASS								



chain nodes :

1 2 4 5 33

ring nodes :

6 7 8 9 10 11 12 13 14 15 16 17 19 20 21 22 23 24 25 26 27 28 29

chain bonds :

1-2 1-11 2-4 2-5 5-14

ring bonds :

6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15 15-16 16-17 19-20 19-23
20-21 21-22 22-23 24-25 24-29 25-26 26-27 27-28 28-29

exact/norm bonds :

1-2 1-11 2-4 2-5 5-14 19-20 19-23 20-21 21-22 22-23

normalized bonds :

6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15 15-16 16-17 24-25 24-29
25-26 26-27 27-28 28-29

isolated ring systems :



containing 6 : 12 : 19 : 24 :

G1:O,S

G4:[*1],[*2]

Match level :

1:CLASS	2:CLASS	4:CLASS	5:CLASS	6:Atom	7:Atom	8:Atom	9:Atom	10:Atom	11:Atom
12:Atom	13:Atom	14:Atom	15:Atom	16:Atom	17:Atom	19:Atom	20:Atom	21:Atom	22:Atom
23:Atom	24:Atom	25:Atom	26:Atom	27:Atom	28:Atom	29:Atom	33:CLASS	34:CLASS	



chain nodes :

1 2 4 5

ring nodes :

6 7 8 9 10 11 12 13 14 15 16 17 19 20 21 22 23

chain bonds :

1-2 1-11 2-4 2-5 5-14

ring bonds :

6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15 15-16 16-17 19-20 19-23
20-21 21-22 22-23

exact/norm bonds :

1-2 1-11 2-4 2-5 5-14 19-20 19-23 20-21 21-22 22-23

normalized bonds :

6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15 15-16 16-17

isolated ring systems :

containing 6 : 12 : 19 :

G1:O,S

G4

Match level :

1:CLASS 2:CLASS 4:CLASS 5:CLASS 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 19:Atom 20:Atom 21:Atom 22:Atom
23:Atom 25:CLASS



Windows NT

Printer Test Page

Congratulations!

If you can read this information, you have correctly installed your HP LaserJet 4100 PCL 6 on WS07547.

The information below describes your printer driver and port settings.

Machine Name: WS07547
Printer name: HP LaserJet 4100 PCL 6
Printer model: HP LaserJet 4100 PCL 6
Color support: Yes
Port name(s): LPT1:
Data format: RAW
Share Name:
Location:
Comment:
Driver name: HPBF0422.DLL
Data file: HPBF0424.PMD
Config file: HPBF0420.DLL
Driver version: 4.01
Environment: Windows NT x86
Monitor: HP LaserJet 5 Language Monitor

Files used by this driver:

C:\WINNT\System32\spool\DRIVERS\W32X86\2\HPBF0420.DLL	(4.3.2.89)
C:\WINNT\System32\spool\DRIVERS\W32X86\2\HPBF0421.DLL	(4.3.2.89)
C:\WINNT\System32\spool\DRIVERS\W32X86\2\HPBF0422.DLL	(4.3.2.89)
C:\WINNT\System32\spool\DRIVERS\W32X86\2\HPBF0423.DLL	(4.3.2.89)
C:\WINNT\System32\spool\DRIVERS\W32X86\2\HPBF0424.PMD	
C:\WINNT\System32\spool\DRIVERS\W32X86\2\HPBF0424.DLL	(4.3.2.89)
C:\WINNT\System32\spool\DRIVERS\W32X86\2\HPBF0424.HLP	
C:\WINNT\System32\spool\DRIVERS\W32X86\2\HPBF0425.DLL	(4.3.2.89)
C:\WINNT\System32\spool\DRIVERS\W32X86\2\HPBF0426.DLL	(7.0.0.1)
C:\WINNT\System32\spool\DRIVERS\W32X86\2\HPBAFD32.DLL	(4.5.0)
C:\WINNT\System32\spool\DRIVERS\W32X86\2\HPBFTM32.DLL	(0, 1, 0, 3)
C:\WINNT\System32\spool\DRIVERS\W32X86\2\HPDCMON.DLL	(04.20.00)
C:\WINNT\System32\spool\DRIVERS\W32X86\2\HPDCMON.DLL	(04.20.00)

This is the end of the printer test page.

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
 NEWS 2 "Ask CAS" for self-help around the clock
 NEWS 3 May 10 PROUSDDR now available on STN
 NEWS 4 May 19 PROUSDDR: One FREE connect hour, per account, in both May
 and June 2004
 NEWS 5 May 12 EXTEND option available in structure searching
 NEWS 6 May 12 Polymer links for the POLYLINK command completed in REGISTRY
 NEWS 7 May 17 FRFULL now available on STN
 NEWS 8 May 27 New UPM (Update Code Maximum) field for more efficient patent
 SDIs in CAPlus
 NEWS 9 May 27 CAPlus super roles and document types searchable in REGISTRY
 NEWS 10 May 27 Explore APOLLIT with free connect time in June 2004
 NEWS 11 Jun 22 STN Patent Forums to be held July 19-22, 2004

NEWS EXPRESS MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT
 MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
 AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004

NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS INTER General Internet Information
 NEWS LOGIN Welcome Banner and News Items
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 20:07:05 ON 24 JUN 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 20:07:16 ON 24 JUN 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 JUN 2004 HIGHEST RN 698346-19-9
 DICTIONARY FILE UPDATES: 23 JUN 2004 HIGHEST RN 698346-19-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

=> s l1

SAMPLE SEARCH INITIATED 20:08:05 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1065 TO ITERATE

93.9% PROCESSED 1000 ITERATIONS 2 ANSWERS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 19343 TO 23257
 PROJECTED ANSWERS: 2 TO 129

L2 2 SEA SSS SAM L1

=> s l1 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 155.00 U.S. DOLLARS
 DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
 FULL SEARCH INITIATED 20:08:12 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 20966 TO ITERATE

100.0% PROCESSED 20966 ITERATIONS 24 ANSWERS
 SEARCH TIME: 00.00.01

L3 24 SEA SSS FUL L1

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	155.84	156.05

FILE 'HCAPLUS' ENTERED AT 20:08:15 ON 24 JUN 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Jun 2004 VOL 140 ISS 26
 FILE LAST UPDATED: 23 Jun 2004 (20040623/ED)

This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s 13

L4 9 L3

=> d 14, ibib abs fhitr, 1-9

L4 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
--------------	----------------------

ACCESSION NUMBER:	2004:78612 HCAPLUS
DOCUMENT NUMBER:	140:136371
TITLE:	Photothermographic material
INVENTOR(S):	Nakagawa, Hajime
PATENT ASSIGNEE(S):	Japan
SOURCE:	U.S. Pat. Appl. Publ., 167 pp.
	CODEN: USXXCO
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	7
<u>PATENT INFORMATION:</u>	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004018458	A1	20040129	US 2003-437920	20030515
JP 2003337392	A2	20031128	JP 2002-143410	20020517
JP 2004020645	A2	20040122	JP 2002-171913	20020612
JP 2004020646	A2	20040122	JP 2002-171914	20020612
JP 2004020699	A2	20040122	JP 2002-172635	20020613
JP 2004020843	A2	20040122	JP 2002-174715	20020614
JP 2004020919	A2	20040122	JP 2002-175678	20020617
JP 2004037719	A2	20040205	JP 2002-193341	20020702
<u>PRIORITY APPLN. INFO.:</u>			JP 2002-143410	A 20020517
			JP 2002-171913	A 20020612
			JP 2002-171914	A 20020612
			JP 2002-172635	A 20020613
			JP 2002-174715	A 20020614
			JP 2002-175678	A 20020617
			JP 2002-193341	A 20020702

OTHER SOURCE(S): MARPAT 140:136371


AB The present invention provides a photothermog. material including a support having disposed on one surface of the support, at least one image forming layer contg. a photosensitive silver halide, a non-photosensitive org. silver salt, a reducing agent, a development accelerator and a binder, and at least one protective layer on the identical surface, wherein 50% by mass or more of the binder contained in the image forming layer is a water sol. binder, and the reducing agent is contained in the form of a solid dispersion.

IT **649569-94-8**

RL: TEM (Technical or engineered material use); USES (Uses)
 (photothermog. material contg.)

RN **649569-94-8** HCAPLUS

CN Cyclopentanecarboxylic acid, 2-[4-[[[3-(2,5-dihydro-5-thioxo-1H-tetrazol-1-yl)phenyl]amino]carbonyl]amino]phenyl]-5-hydroxy- (9CI) (CA INDEX NAME)




L4 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
--------------	----------------------

ACCESSION NUMBER: 2001:50635 HCAPLUS
 DOCUMENT NUMBER: 134:115845
 TITLE: Preparation of α,β -annelated butyrolactones as modulators of metabotropic glutamate receptors.
 INVENTOR(S): Stolle, Andreas; Antonicek, Horst-Peter; Lensky, Stephan; Voerste, Arnd; Muller, Thomas; Baumgarten, Jorg; Von Dem Bruch, Karsten; Muller, Gerhard; Stropp, Udo; Horvath, Ervin; De Vry, Jean-Marie-Victor; Schreiber, Rudy
 PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
 SOURCE: PCT Int. Appl., 215 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001004107	A1	20010118	WO 2000-EP6105	20000630
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG DE 19932621 A1 20010426 DE 1999-19932621 19990713 PRIORITY APPLN. INFO.: DE 1999-19932621 A 19990713 OTHER SOURCE(S): MARPAT 134:115845 GI				



AB Title compds. [I; A = CH₂, CO, C(OH)R₄, (CH₂)_aCHR₅; a = 0-4; R₄ = H, alkyl; R₅ = Ph; R₁ = H, alkyl, cycloalkyl, (benzocondensed) (substituted) heterocyclyl; R₂, R₃ = H, alkyl; DE = CH₂COCH₂, CH₂CH(OH)CH₂, CH₂C(OH)(CH₂OH)CH₂, CH₂C(:CR₃₁R₃₂)CH₂, etc.; R₃₁, R₃₂ = H, Ph, alkyl], were prepd. for treatment of cerebral ischemia, skull/brain trauma, pain, and CNS-induced cramps (no data). Thus, N-[(3a''S*,6a''S*)-4-(5-methylenehexahydrocyclopenta[c]furan-1-on-6ylmethyl)phenyl]bromoacetamide

(prepn. given), Et₃N, and morpholine were refluxed 20 h in PrOH to give 87% N-[(3a''S*,6a''S*)-4-(5-methylenehexahydrocyclopenta[c]furan-1-on-6ylmethyl)-phenyl]-N-morpholineacetamide.

IT **321128-68-1P**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of α,β -annelated butyrolactones as modulators of metabotropic glutamate receptors)

RN **321128-68-1 HCAPLUS**

CN Urea, N-(2,6-dicyclopentylphenyl)-N'-[4-[[[(3aR,6aR)-tetrahydro-5-methylene-3-oxo-1H-cyclopenta[c]furan-3a(3H)-yl]methyl]phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2004 ACS on STN

Full
Text

Citing
References

ACCESSION NUMBER:

2000:15184 HCAPLUS

DOCUMENT NUMBER:

132:64256

TITLE:

Preparation of non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune and respiratory diseases

INVENTOR(S):

Duplantier, Allen Jacob; Milici, Anthony John; Chupak, Louis Stanley

PATENT ASSIGNEE(S):

Pfizer Products Inc., USA

SOURCE:

PCT Int. Appl., 120 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English


FAMILY ACC. NUM. COUNT:

1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000000477	A1	20000106	WO 1999-IB973	19990531
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

FS 3D CONCORD
 MF C18 H20 N2 O
 SR CAOLD
 LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS
 (*File contains numerically searchable property data)
 DT.CA Caplus document type: Journal
 RL.NP Roles from non-patents: NORL (No role in record)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

FILE 'CAOLD' ENTERED AT 20:11:34 ON 24 JUN 2004

=> fil reg; d acc 101728-12-5; fil CAOLD

FILE 'REGISTRY' ENTERED AT 20:11:46 ON 24 JUN 2004

ANSWER 1 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 101728-12-5 REGISTRY
 CN Carbanilide, 4-bromo-4'-cyclopentylthio- (6CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C18 H19 Br N2 S
 SR CAOLD
 LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS
 (*File contains numerically searchable property data)
 DT.CA Caplus document type: Journal
 RL.NP Roles from non-patents: NORL (No role in record)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

FILE 'CAOLD' ENTERED AT 20:11:46 ON 24 JUN 2004

=> fil reg; d acc 102016-04-6; fil CAOLD

FILE 'REGISTRY' ENTERED AT 20:12:06 ON 24 JUN 2004

ANSWER 1 REGISTRY COPYRIGHT 2004 ACS on STN

RN 102016-04-6 REGISTRY

CN Carbanilide, 4-cyclopentyl- (6CI) (CA INDEX NAME)

FS 3D CONCORD

MF C18 H20 N2 O


SR CAOLD

LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS

(*File contains numerically searchable property data)

DT.CA Caplus document type: Journal

RL.NP Roles from non-patents: NORL (No role in record)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

FILE 'CAOLD' ENTERED AT 20:12:07 ON 24 JUN 2004

=> fil reg; d acc 102016-04-6; fil CAOLD

FILE 'REGISTRY' ENTERED AT 20:12:25 ON 24 JUN 2004

ANSWER 1 REGISTRY COPYRIGHT 2004 ACS on STN

RN 102016-04-6 REGISTRY

CN Carbanilide, 4-cyclopentyl- (6CI) (CA INDEX NAME)

FS 3D CONCORD

MF C18 H20 N2 O


SR CAOLD

LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS

(*File contains numerically searchable property data)

DT.CA Caplus document type: Journal

RL.NP Roles from non-patents: NORL (No role in record)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

FILE 'CAOLD' ENTERED AT 20:12:26 ON 24 JUN 2004

=> fil reg; d acc 102017-35-6; fil CAOLD

FILE 'REGISTRY' ENTERED AT 20:12:49 ON 24 JUN 2004

ANSWER 1 REGISTRY COPYRIGHT 2004 ACS on STN

RN 102017-35-6 REGISTRY

CN Carbanilide, 4-cyclopentylthio- (6CI) (CA INDEX NAME)

FS 3D CONCORD

MF C18 H20 N2 S


SR CAOLD

LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS

(*File contains numerically searchable property data)

DT.CA Caplus document type: Journal

RL.NP Roles from non-patents: NORL (No role in record)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

FILE 'CAOLD' ENTERED AT 20:12:49 ON 24 JUN 2004

=> fil reg; d acc 102552-49-8; fil CAOLD

FILE 'REGISTRY' ENTERED AT 20:13:07 ON 24 JUN 2004

ANSWER 1 REGISTRY COPYRIGHT 2004 ACS on STN

RN 102552-49-8 REGISTRY

CN Carbanilide, 4-cyclopentyl-4'-ethoxythio- (6CI) (CA INDEX NAME)

FS 3D CONCORD

MF C20 H24 N2 O S


SR CAOLD

LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS

(*File contains numerically searchable property data)

DT.CA Caplus document type: Journal

RL.NP Roles from non-patents: NORL (No role in record)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

FILE 'CAOLD' ENTERED AT 20:13:08 ON 24 JUN 2004

=>

CA 2336625	AA	20000106	CA 1999-2336625	19990531
AU 9938416	A1	20000117	AU 1999-38416	19990531
AU 758939	B2	20030403		
BR 9911701	A	20010320	BR 1999-11701	19990531
EP 1091943	A1	20010418	EP 1999-921046	19990531
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
TR 200003848	T2	20010621	TR 2000-200003848	19990531
JP 2002519344	T2	20020702	JP 2000-557238	19990531
NZ 508033	A	20021220	NZ 1999-508033	19990531
ZA 9903777	A	20001204	ZA 1999-3777	19990604
US 6306887	B1	20011023	US 1999-338832	19990623
US 6355662	B1	20020312	US 1999-403846	19991026
NO 2000006600	A	20010221	NO 2000-6600	20001222
HR 2000000917	A1	20020228	HR 2000-917	20001229
BG 105190	A	20011231	BG 2001-105190	20010126
PRIORITY APPLN. INFO.:			US 1998-91180P	P 19980630
			WO 1999-IB973	W 19990531
			US 1999-338832	A3 19990623

OTHER SOURCE(S): MARPAT 132:64256
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The title compds. [I; A = (un)substituted aryl, heteroaryl, heterocyclyl, etc.; B = II-IV, etc.; E = a single bond, O, CH:CH, etc.; X = O, S, SO, SO₂, etc.; Y = CO, CS, SO₂, etc.; m = 0-2; n = 1-2; p = 1-2; R = CO₂R₅; CONO, etc.; R₂, R₃ = H, alkyl, alkenyl, etc.; R₂R₃ = (un)substituted spiro(C₃-14)carbocyclic ring; R₂-R₄ together with the C and N atoms to which they are attached = (un)substituted heteroaryl, heterocyclyl; R₅ = H, alkyl, cycloalkyl, aryl; R₆ = H, alkyl, (CH₂)_r-cycloalkyl, etc.; r = 0-2], useful in treating or preventing an inflammatory, autoimmune or respiratory disease such as asthma, multiple sclerosis, rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, psoriasis, transplant rejection, and atherosclerosis, by inhibiting cell adhesion and consequent or assocd. pathogenic processes subsequently mediated by VLA-4 (no data), were prepd. E.g., a multi-step synthesis of the title compd. V, was given. Compds. I are effective at 20 µg - 0.5 mg/kg/day.

IT **253346-52-0P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune and respiratory diseases)

RN **253346-52-0** HCAPLUS

CN 5-Oxazoleacetic acid, 2-[1-[[[4-[[[(2-cyclopentylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]-3-methylbutyl]-4,5-dihydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
--------------	----------------------


ACCESSION NUMBER: 1997:290138 HCAPLUS
 DOCUMENT NUMBER: 126:263962
 TITLE: 13-substituted milbemycin 5-oxime derivatives, their preparation and their use against insects and other pests
 INVENTOR(S): Sato, Kazuo; Saito, Akio; Toyama, Toshimitsu
 PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
 SOURCE: Eur. Pat. Appl., 164 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 765879	A1	19970402	EP 1996-307092	19960927
EP 765879	B1	20010214		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2186650	AA	19970330	CA 1996-2186650	19960927
NO 9604090	A	19970401	NO 1996-4090	19960927
AU 9665861	A1	19970410	AU 1996-65861	19960927
AU 707152	B2	19990701		
ZA 9608183	A	19970425	ZA 1996-8183	19960927
AT 199154	E	20010215	AT 1996-307092	19960927
ES 2155172	T3	20010501	ES 1996-307092	19960927
CZ 288178	B6	20010516	CZ 1996-2862	19960927
PT 765879	T	20010531	PT 1996-307092	19960927
CN 1153177	A	19970702	CN 1996-119229	19960929
CN 1077110	B	20020102		
IL 119321	A1	20010520	IL 1996-119321	19960929
JP 09151188	A2	19970610	JP 1996-259445	19960930
JP 3132644	B2	20010205		
US 5861429	A	19990119	US 1996-723835	19960930
RU 2128181	C1	19990327	RU 1996-120138	19960930
HK 1003937	A1	20010629	HK 1998-103114	19980415
GR 3035565	T3	20010629	GR 2001-400411	20010313

PRIORITY APPLN. INFO.: JP 1995-252965 A 19950929

OTHER SOURCE(S): MARPAT 126:263962

GI



I

AB Title compds. I [R1 = Me, Et, CHMe2, CHMeEt; X = CO, CH2; R2 = alkyl; R22 = (CH2)2-5; n = 0, 1; R3 is nitro, (un)substituted amino, alkoxy, alkoxyalkoxy] having valuable acaricidal, insecticidal and anthelmintic activities were prepd. Thus, 15-hydroxy-5-oxomilbemycin A4 was acylated with 1-(4-nitrophenyl)cyclopentanecarboxylic acid, oximated, silylated, reduced to the amine, acetylated, and desilylated to give 13-[1-(4-nacetylaminophenyl)cyclopentanecarbonyloxy]-5-hydroxyiminomilbemycin A4 which gave 100% kill of cat fleas at 1 ppm in a bovine serum artificial skin prepn.

IT **188844-09-9P**


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 13-substituted milbemycin 5-oxime derivs. as insecticides)

RN **188844-09-9** HCAPLUS

CN Milbemycin B, 5-demethoxy-28-deoxy-6,28-epoxy-25-ethyl-5-(hydroxyimino)-13-[[[1-[4-[[[(phenylamino)carbonyl]amino]phenyl]cyclopentyl]carbonyl]oxy]-, (6R,13R,25R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as described by E or Z.



L4 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Citing
Text References

ACCESSION NUMBER: 1969:479470 HCAPLUS
DOCUMENT NUMBER: 71:79470

TITLE: Tuberculostatic N,N'-diarylthioureas. II
 AUTHOR(S): Wagner, Wolf Helmut; Winkelmann, Erhardt
 CORPORATE SOURCE: Farbwerke Hoechst A.-G., Frankfurt/M.-Hoechst, Fed. Rep. Ger.
 SOURCE: Arzneimittel-Forschung (1969), 19(5), 719-30
 CODEN: ARZNAD; ISSN: 0004-4172
 DOCUMENT TYPE: Journal
 LANGUAGE: German

AB RNHCSNHR1 (where R = p- and (or) m-substituted phenyl; and R1 = phenyl carrying a heterocyclic or condensed heterocyclic substituent) (I) prepd. by known methods which are reviewed, were tested for tuberculostatic (I) prepd. by known methods which are reviewed, were tested for properties. I (R = p-BuOC6H4 or p-iso-BuOC6H4; R1 = p-[2-(2-pyridyl)vinyl]phenyl) were the most active, but showed long-term toxic effects in mice. In general the pyridyl residue conferred high antitubercular activity on I. It could be replaced by quinolyl, but replacement by other heterocycles or substitution in the pyridyl or quinolyl group caused loss of activity. Similarly the alkoxy residues in the R-substituent could be replaced by alkyl residues of the same chain length without loss of activity. The S atom is also essential for antitubercular activity. The ureas and carbamides corresponding to active thioureas showed no antitubercular activity. I (R = p-iso-BuOC6H4, p-Me2CHCH2CH2OC6H4, or p-Me2CHCH2-CH2C6H4, R1 = p-[2-(2-pyridyl)ethyl]phenyl; or R = p-iso-BuOC6H4, R1 = [2-(4-pyridyl)ethyl]phenyl) had high antitubercular activity combined with lower toxicity than the corresponding pyridylvinyl derivs. I (R = p-BuOC6H4; R1 = p-Me2-NC6H4) showed antileprotic activity.


IT 10400-12-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antitubercular activity of)

RN 10400-12-1 HCAPLUS

CN Carbanilide, 4-cyclopentyl-4'-[2-(2-pyridyl)ethyl]thio- (7CI, 8CI) (CA INDEX NAME)



L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
-----------	-------------------


ACCESSION NUMBER:	1966:473373 HCAPLUS
DOCUMENT NUMBER:	65:73373
ORIGINAL REFERENCE NO.:	65:13666c-e
TITLE:	α -Substituted 2-pyridinethioacetamides
INVENTOR(S):	Sause, Henry W.
PATENT ASSIGNEE(S):	G.D. Searle and Co.
SOURCE:	10 pp.
DOCUMENT TYPE:	Patent
LANGUAGE:	Unavailable
FAMILY ACC. NUM. COUNT:	1
<u>PATENT INFORMATION:</u>	

PATENT NO.

KIND DATE

APPLICATION NO. DATE

 BE 669165 19660303 BE 19640903
 PRIORITY APPLN. INFO.: US
 AB Title products, with pharmacol. properties are prepd. as follows: H₂S gas is passed through a soln. of 3 g. α -phenyl-2-pyridinoacetonitrile (I) and 1.6 g. Et₃N in 120 g. pyridine for 17 hrs. at room temp. The solvent is evapd. in vacuo and the residue crystd. from hexane-iso-PrOH to give α -phenyl-2-pyridinethioacetamide (II), m. 137.5-8.0°. H₂S gas is passed through a soln. of 11.4 g. α -(4-chlorophenyl)-2-pyridinoacetonitrile and 3.6 g. Et₃N in 100 g. pyridine for 6 hrs. at room temp., and then left for 17 hrs. The solvent is evapd. in vacuo, and the residue crystd. from C₆H₆-iso-PrOH to give α -(4-chlorophenyl)-2-pyridinethioacetamide, m. 160-60.5°. A mixt. of 2.12 g. I 1.11 g. S₅P₅, and 8.8 g. xylene is heated with stirring for 4.5 hrs. The mixt. is cooled, dild. with benzene, and filtered. The filtrate is evapd. in vacuo, and the residue crystd. from heptane-iso-PrOH to give II, m. 135-6°. A soln. of 2.45 g. methyl α -phenyl-2-pyridinedithioacetate in 8 g. MeOH is added to 20 g. MeOH satd. with NH₃. The mixt. is left overnight, and the solvent evapd. The residue is crystd. from heptane-iso-PrOH to give II, m. 135-6°.
 IT 10400-12-1, Carbanilide, 4-cyclopentyl-4'-[2-(2-pyridyl)ethyl]thio- (prepn. of)
 RN 10400-12-1 HCAPLUS
 CN Carbanilide, 4-cyclopentyl-4'-[2-(2-pyridyl)ethyl]thio- (7CI, 8CI) (CA INDEX NAME)



L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
ACCESSION NUMBER:	1966:473372 HCAPLUS
DOCUMENT NUMBER:	65:73372
ORIGINAL REFERENCE NO.:	65:13665h,13666a-c
TITLE:	Tuberculostatic thioureas
PATENT ASSIGNEE(S):	Farbwerke Hoechst A.-G.
SOURCE:	12 pp.
DOCUMENT TYPE:	Patent
LANGUAGE:	Unavailable
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NL 6514396		19660509	NL	
PRIORITY APPLN. INFO.:		DE	19641106	


GI For diagram(s), see printed CA Issue.
 AB The title compds. (Ia) are prepd. by reaction of equimolar amts. of substituted anilines and isothiocyanates or compds. reacting as such. The reaction is optionally carried out in a 5- to 20-fold amt. of an org. solvent (such as a low-boiling alc., ether, or aromatic hydrocarbon) at the b.p. of the solvent. The products crystallize on cooling and are useful in oral and cutaneous treatment of tuberculosis and leprosy. Thus,

19.8 g. p-(α -pyridylethyl)aniline (I), b2 156-8°, prepd. by condensing p-nitrobenzaldehyde with α -picoline in boiling Ac2O, and reducing the product with Raney Ni in EtOH, was treated in 100 ml. EtOH with 20.7 g. p-butoxyphenyl isothiocyanate; the mixt. warmed 15 min. at 75°, and kept several hrs. at room temp. The ppt. was filtered off to give 82% N-(p-butoxyphenyl)-N-[p-(α -pyridylethyl)phenyl]thiourea (II), m. 140°. II could also be prepd. by reaction of 16.5 g. p-butoxyaniline and 24 g. p-(α -pyridylethyl)-phenylisothiocyanate in 100 ml. EtOH, heating 15 min. at 75°, and working-up. Similarly, the following thioureas were also prepd.: N-(p-isobutoxyphenyl)-N'-[p-(α -pyridylethyl)phenyl]-, m. 115°; N-(p-isoamyloxyphenyl)-N'-[p-(α -pyridylethyl)phenyl]-, m. 141°; N-(p-isobutoxyphenyl)-N'-[p-(γ -pyridylethyl)phenyl]-, m. 134°; N-(p-isoamylphenyl)-N'-[p-(α -pyridylethyl)-phenyl]-, m. 124°; N-(p-cyclopentylphenyl)-N'-[p-(α -pyridylethyl)phenyl]-, m. 127°; N-(p-cyclohexylphenyl)-N'-[p-(α -pyridylethyl)phenyl]-, m. 139°.

IT **10400-12-1**, Carbanilide, 4-cyclopentyl-4'-[2-(2-pyridyl)ethyl]thio- (prepn. of)

RN **10400-12-1** HCAPLUS

CN Carbanilide, 4-cyclopentyl-4'-[2-(2-pyridyl)ethyl]thio- (7CI, 8CI) (CA INDEX NAME)



L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER:	1964:454881 HCAPLUS
DOCUMENT NUMBER:	61:54881
ORIGINAL REFERENCE NO.:	61:9505f-h
TITLE:	Preparation of thiourea derivatives
INVENTOR(S):	Hilmer, Hans; Winkelmann, Ehrhardt
PATENT ASSIGNEE(S):	Farbwerke Hoechst AG
SOURCE:	3 pp.
DOCUMENT TYPE:	Patent
LANGUAGE:	Unavailable
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1169943		19640514	DE	19620228

GI For diagram(s), see printed CA Issue.


AB Thiourea compds. (I), in which R1 is a normal or branched C4-. alkyl or alkoxy group or a cyclopentylgroup and R2 is a piperidino or morpholino group, are useful against tuberculosis and leprosy. A soln. of 20.4 g. p-(2-piperidinoethyl)aniline and 20.7 g. p-iso-BuOC6H4NCS in 75 ml. EtOH was heated 20 min. at 75° and treated with an alc. HCl soln. to yield 63% I (R1 = iso-BuO, R2 = piperidino).HCl (II), m. 190°. A soln. of 16.5 g. p-iso-BuOC6H4NH2 (III) and 24.6 g. p-(2-piperidinoethyl)phenyl iso-thiocyanate in 75 ml. EtOH (20 min. at 75°) yielded also II. Similarly were prepd. I.HCl (R1, R2, m.p.,

and % yield given): BuO, piperidino, 190°, 63; iso-AmO, piperidino, 207°, 75; iso-AmO, morpholino, 241°, 63; iso-BuO, morpholino (IV), 241° 67; iso-Am, morpholino, 129°, 54; cyclopentyl, morpholino, 145°, 73. A soln. of 16.5 g. III in 100 ml. C₆H₆ was treated 15 min. with NH₃ gas under cooling, 7.6 g. CS₂ was added under stirring, and the soln. treated another 15 min. with NH₃ to yield 22 g. p-iso-BuOC₆H₄NHCS₂NH₄ (V), m. 81° (decompn.). A soln. of 25.8 g. V and 20.6 g. p-(2-morpholinoethyl)aniline in 100 ml. EtOH was refluxed 2 hrs. and treated with alc. HCl soln. to yield IV.

IT 95805-72-4, Carbanilide, 4-cyclopentyl-4'-(2-morpholinoethyl)thio- (prepn. of)

RN 95805-72-4 HCAPLUS

CN Carbanilide, 4-cyclopentyl-4'-(2-morpholinoethyl)thio- (7CI) (CA INDEX NAME)



L4 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER:	1958:104298 HCAPLUS
DOCUMENT NUMBER:	52:104298
ORIGINAL REFERENCE NO.:	52:18412i,18413a-i,18414a-c
TITLE:	p-Cyclopentylacetophenone and its derivatives
AUTHOR(S):	Hai, P. V.; Buu-Hoi, Ng. Ph.; Xuong, Ng. D.
CORPORATE SOURCE:	Univ. Paris
SOURCE:	Journal of Organic Chemistry (1958), 23, 39-42 CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE:	Journal
LANGUAGE:	Unavailable
OTHER SOURCE(S):	CASREACT 52:104298

GI For diagram(s), see printed CA Issue.

AB cf. C.A. 51, 6850i. The use of the title compd. (I) prepd. from cyclopentylbenzene (II) as an intermediate for the synthesis of various aromatic and heterocyclic cyclopentyl compds., especially p-cyclopentylaniline (III) was investigated and a large no. of derivs. prepd. for evaluation of their tuberculostatic activity. Reinvestigation of the various methods proposed for the synthesis of II (cf. Cagniant, et al., C.A. 41, 6211g) showed condensation of cyclopentanol (IV) with C₆H₆ to be the most satisfactory. AlCl₃ (17 g.) in 120 ml. C₆H₆ stirred vigorously with dropwise addn. of 23 g. IV and the mixt. treated with 17 g. AlCl₃ and 20 g. IV, poured onto ice and the org. layer washed repeatedly with 10% NaOH, the H₂O-washed org. soln. dried (CaCl₂) and distd. yielded 54% II, b. 215-17°, n_D20 1.5230 and 15-20% dicyclopentylbenzene, b₁₅ 178-80°, n_D20 1.5427. II (14.6 g.) and 8.5 g. AcCl in 60 ml. dry CS₂ stirred with portionwise addn. of 14.8 g. AlCl₃ and the mixt. kept overnight at room temp., heated on a steam bath until HCl evolution stopped and decompd. with ice, the product extd. with CHCl₃ and worked up as usual yielded 79% I, b₁₅ 170°, n_D20 1.5509; oxime (Ia), m. 104° (alc.); semicarbazone, m. 233° (alc.). I (3.8 g.) degraded at 60-70° with aq. NaOBr (9.6 g. Br in 6.4 g. NaOH in H₂O) yielded 42% p-cyclopentylbenzoic acid, m. 200° (C₆H₆). Similarly, 14.8 g. II, 9.2 g. EtCOCl or 10.6 g. PrCOCl, and 14.8 g. AlCl₃ in 60 ml. dry CS₂ gave 80% yields of p-cyclopentylpropiophenone, b₁₇ 182°, n_D19 1.5439, and p-cyclopentylbutyrophenone, b₂₇


204-6°, nD₁₉ 1.5437. Equimolar amts. of I and the appropriate aldehyde shaken in warm alc. with a few drops of 20% aq. NaOH and the ppt. recrystd. (alc.) gave a series of chalcones, p-C₅H₉C₆H₄COCH:CHR (R and m.p. given): 2-furyl, 99°; 2-thenyl, 105°; 1-naphthyl, 98°; 3-ClC₆H₄, 106°; 3-MeOC₆H₄, 84°. Ia (20.3 g.) in 100 ml. dry Et₂O stirred with portionwise addn. of 31 g. finely powd. PCl₅ and the Et₂O evapd., the residue decompd. with ice and the ppt. recrystd. (alc.) gave 16 g. p-C₅H₉C₆H₄NHAc, m. 136°, hydrolyzed (20.3 g.) by refluxing 2 hrs. with 30 ml. HCl in 100 ml. alc. and working up to yield 12 g. III, b₂₂ 165-7°, nD₁₉ 1.5710. III (3.3 g.) and 4 g. (AcCH₂)₂ refluxed 30 min. and distd. in vacuo gave 3 g. 1-p-cyclopentyl-2,5-dimethylpyrrole, b₂₅ 207° m. 42° (MeOH). III (0.8 g.), 1.2 g. 2,3-dichloro-1,4-naphthoquinone, and 1.2 g. NaOAc refluxed 1 hr. in alc. and the ppt. formed on cooling recrystd. (alc.-C₆H₆) gave violet needles of 2-chloro-3-(p-cyclopentylanilino)-1,4-naphthoquinone, m. 158°. Similarly 1 g. III, 0.9 g. chloranil, and 2 g. NaOAc refluxed 1 hr. in alc. gave brown leaflets of 3,6-bis(p-cyclopentylanilino)-2,5-dichloro-1,4-benzoquinone, m. 309° (PhMe). Tetrachlorophthalic anhydride (1 g.) in 15 ml. boiling AcOH treated dropwise with 0.6 g. III and the mixt. refluxed a few min. cooled and the solid crystd. (AcOH) gave N-(p-cyclopentylphenyl)tetrachlorophthalimide, m. 242°. In view of the pronounced in vitro tuberculostatic activity of various N-arylglycines (B. H., et al., C.A. 52, 3011d). III (3.2 g.), 2 g. ClCH₂CO₂H, and 6 g. NaOAc were heated in H₂O 1 hr. on a steam bath and the cooled soln. dild. with H₂O. filtered and the ppt. taken up in 10% aq. (NH₄)₂CO₃, the filtered soln. acidified with AcOH and the ppt. crystd. H₂O to yield 50% p-C₅H₉C₆H₄NHCH₂CO₂H, m. 199°. III (6.4 g.), 8 g. BrCH₂CO₂Et, and 15 g. NaOAc heated 3 hrs. on a steam bath and dild. with 50 ml. H₂O, extd. with CHCl₃ and the washed and dried ext. evapd., the residue fractionated and the ester (77%, b₁₅ 219-21°) crystd. (petr. ether) gave p-C₅H₉C₆H₄NHCH₂CO₂Et (V), m. 42°. V (2.5 g.) and 1.5 g. 98% N₂H₄.H₂O refluxed 2 hrs. in 20 ml. alc. and cooled yielded 98% p-C₅H₉C₆H₄NHCH₂CONHNH₂, m. 153°. The condensation of III with various aryl isothiocyanates in equimolar amts. by heating 30 min. at 50-60° in alc. and crystn. (alc.) of the product gave a series of bitter tasting substituted p-cyclopentylthiocarbanilides, p-C₅H₉C₆H₄NHCSNHR (R and m.p. given): Ph, 142°; 4-FC₆H₄, 177°; 4-ClC₆H₄, 208°; 4-BrC₆H₄, 215°; 4-Me-C₆H₄, 158°; 2,4-Me₂C₆H₃, 145°; 4-EtC₆H₄, 130°; 4-EtOC₆H₄, 167°; 4-Me₂CH(CH₂)₂OC₆H₄, 128°; 2-PhC₆H₄, 187°; 4-C₅H₉C₆H₄, 203°. These compds. with the exception of the 4-BrC₆H₄ and 2-PhC₆H₄ derivs. showed considerable in vitro tuberculostatic activity against Mycobacterium tuberculosis (H37 RvD) at a concn. of 10 γ/ml. Dubos culture medium. A no. of similarly synthesized substituted p-cyclopentylcarbanilides, p-C₅H₉C₆H₄NHCONHR (R and m.p. given): Ph, 195°; p-ClC₆H₄, 229°; 2-PhC₆H₄, 169°; 2-ClO₂H₇, 220°, were found inactive against M. tuberculosis. Fischer indolization of I phenylhydrazone readily afforded 2-(p-cyclopentylphenyl)indole (VI). I (3 g.) and 2 g. PhNHNH₂ heated a few min. at 140-50° with loss of H₂O and the crude phenylhydrazone heated 15 min. at 185-95° with 7 g. finely powd., fused ZnCl₂, the cooled mixt. treated with AcOH and extd. with C₆H₆, the H₂O-washed ext. dried (Na₂SO₄) and evapd., the residue distd. in vacuo and the fraction, b₁₃ 270-2° recrystd. (C₆H₆-alc.) yielded 70% VI, m. 236°; picrate, deep-violet. Isatin (1 mole) and 1 mole I (and its higher homologs) gently refluxed 72 hrs. on a steam bath with 20% alc. KOH (3 moles KOH) and the soln. dild. with H₂O, the neutral impurities extd. with Et₂O and the aq. layer acidified with AcOH, the pptd. cinchonic acid washed with H₂O and recrystd. (alc.) gave 30% to 80-5% yields of substituted 2-(p-cyclopentylphenyl)cinchonic acids (VII)

from p-C5H9C6H4COPr and I resp. (R, R' and m.p. given: H, H, 248°; H, Br, 254° (decompn.); H, Me, 230°; Me, H, 315°; Et, H, 288°. VII heated above the m.p., the decarboxylation product distd. in vacuo and recrystd. (alc.) gave the corresponding quinolines (R, R' and m.p. given): H, H, 110°; H, Me, 142°.

IT 1536-16-9, Carbanilide, 4-cyclopentyl-4'-fluorothio-
(prepn. of)

RN 1536-16-9 HCAPLUS

CN Carbanilide, 4-cyclopentyl-4'-fluorothio- (6CI, 8CI) (CA INDEX NAME)



=> file caold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	45.17	201.22
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-6.24	-6.24

FILE 'CAOLD' ENTERED AT 20:08:45 ON 24 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d his

(FILE 'HOME' ENTERED AT 20:07:05 ON 24 JUN 2004)

FILE 'REGISTRY' ENTERED AT 20:07:16 ON 24 JUN 2004

L1 STRUCTURE UPLOADED
L2 2 S L1
L3 24 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 20:08:15 ON 24 JUN 2004

L4 9 S L3

FILE 'CAOLD' ENTERED AT 20:08:45 ON 24 JUN 2004

=> s l3

L5 3 L3

=> d 15, all, 1-3

L5 ANSWER 1 OF 3 CAOLD COPYRIGHT 2004 ACS on STN

Full
Text

AN CA65:13666c CAOLD
 TI 2-pyridinethioacetamides (α -substituted)
 PA Searle, G. D., & Co.
 DT Patent
 TI α -substituted 2-pyridinethioacetamides
 AU Sause, Henry W.
 DT Patent

PATENT NO. KIND DATE

PI BE 669165

IT 10400-12-1 10400-13-2 10400-14-3 10400-15-4

L5 ANSWER 2 OF 3 CAOLD COPYRIGHT 2004 ACS on STN

Full
Text

AN CA61:9505f CAOLD
 TI thiourea derivs.
 AU Hilmer, Hans; Winkelmann, E.
 PA Farbwerke Hoechst A.-G.
 DT Patent

PATENT NO. KIND DATE

PI DE 1169943

IT 95747-66-3 95805-72-4 100978-51-6 101547-98-2 101548-00-9 101982-61-0
102049-08-1

L5 ANSWER 3 OF 3 CAOLD COPYRIGHT 2004 ACS on STN

AN CA52:18412i CAOLD
 TI p-cyclopentylacetophenone and its derivs.
 AU Hai, P. V.; Buu-Hoi, Ng. Ph.; Xuong, Ng. D.
 IT 700-88-9 1536-16-9 19936-22-2 20029-53-2 56026-22-3 65429-17-6
65429-18-7 80649-39-4 85602-98-8 85689-77-6 100450-94-0 101116-39-6
101581-77-5 101728-12-5 101728-34-1 101728-45-4 101789-33-7
101789-35-9 101884-12-2 101889-75-2 102004-95-5 102016-04-6
102017-35-6 102160-87-2 102237-35-4 102237-50-3 102311-06-8
102313-63-3 102448-18-0 102458-17-3 102458-18-4 102552-49-8
102747-60-4 102750-83-4 102886-80-6 102888-04-0 103279-65-8
106275-01-8 110052-67-0 110663-59-7 110664-10-3 110664-31-8 111029-72-2
111065-27-1 112578-58-2 113649-89-1 114889-54-2 115163-39-8 131977-11-2


=> fil reg; d acc 10400-12-1; fil CAOLD

FILE 'REGISTRY' ENTERED AT 20:09:07 ON 24 JUN 2004

ANSWER 1 REGISTRY COPYRIGHT 2004 ACS on STN

RN 10400-12-1 REGISTRY
 CN Carbanilide, 4-cyclopentyl-4'-[2-(2-pyridyl)ethyl]thio- (7CI, 8CI) (CA
 INDEX NAME)
 FS 3D CONCORD
 MF C25 H27 N3 S
 LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, TOXCENTER

(*File contains numerically searchable property data)
 DT.CA CAplus document type: Journal; Patent
 RL.P Roles from patents: NORL (No role in record)
 RL.NP Roles from non-patents: BIOL (Biological study); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


3 REFERENCES IN FILE CA (1907 TO DATE)
 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

FILE 'CAOLD' ENTERED AT 20:09:07 ON 24 JUN 2004

=> fil reg; d acc 95805-72-4; fil CAOLD

FILE 'REGISTRY' ENTERED AT 20:09:19 ON 24 JUN 2004

ANSWER 1 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 95805-72-4 REGISTRY
 CN Carbanilide, 4-cyclopentyl-4'-(2-morpholinoethyl)thio- (7CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C24 H31 N3 O S
 LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS
 (*File contains numerically searchable property data)
 DT.CA CAplus document type: Patent
 RL.P Roles from patents: NORL (No role in record)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

FILE 'CAOLD' ENTERED AT 20:09:19 ON 24 JUN 2004

=> fil reg; d acc 1536-16-9; fil CAOLD

FILE 'REGISTRY' ENTERED AT 20:09:31 ON 24 JUN 2004

ANSWER 1 REGISTRY COPYRIGHT 2004 ACS on STN

RN 1536-16-9 REGISTRY

CN Carbanilide, 4-cyclopentyl-4'-fluorothio- (6CI, 8CI) (CA INDEX NAME)

FS 3D CONCORD


MF C18 H19 F N2 S

LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS

(*File contains numerically searchable property data)

DT.CA Caplus document type: Journal

RL.NP Roles from non-patents: NORL (No role in record)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

FILE 'CAOLD' ENTERED AT 20:09:32 ON 24 JUN 2004

=> fil reg; d acc 1536-16-9; fil CAOLD

FILE 'REGISTRY' ENTERED AT 20:10:09 ON 24 JUN 2004

ANSWER 1 REGISTRY COPYRIGHT 2004 ACS on STN

RN 1536-16-9 REGISTRY

CN Carbanilide, 4-cyclopentyl-4'-fluorothio- (6CI, 8CI) (CA INDEX NAME)

FS 3D CONCORD


MF C18 H19 F N2 S

LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS

(*File contains numerically searchable property data)

DT.CA Caplus document type: Journal

RL.NP Roles from non-patents: NORL (No role in record)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

FILE 'CAOLD' ENTERED AT 20:10:10 ON 24 JUN 2004

=> fil reg; d acc 101728-12-5; fil CAOLD

FILE 'REGISTRY' ENTERED AT 20:10:25 ON 24 JUN 2004

ANSWER 1 REGISTRY COPYRIGHT 2004 ACS on STN

RN 101728-12-5 REGISTRY

CN Carbanilide, 4-bromo-4'-cyclopentylthio- (6CI) (CA INDEX NAME)

FS 3D CONCORD

MF C18 H19 Br N2 S


SR CAOLD

LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS

(*File contains numerically searchable property data)

DT.CA Caplus document type: Journal

RL.NP Roles from non-patents: NORL (No role in record)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

FILE 'CAOLD' ENTERED AT 20:10:26 ON 24 JUN 2004

=> fil reg; d acc 102004-95-5; fil CAOLD

FILE 'REGISTRY' ENTERED AT 20:10:40 ON 24 JUN 2004

ANSWER 1 REGISTRY COPYRIGHT 2004 ACS on STN

RN 102004-95-5 REGISTRY

CN Glycine, N-(p-cyclopentylphenyl)-, ethyl ester (6CI) (CA INDEX NAME)


FS 3D CONCORD

MF C15 H21 N O2

SR CAOLD

LC STN Files: BEILSTEIN*, CAOLD

(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

FILE 'CAOLD' ENTERED AT 20:10:41 ON 24 JUN 2004

=> fil reg; d acc 113649-89-1; fil CAOLD

FILE 'REGISTRY' ENTERED AT 20:10:56 ON 24 JUN 2004

ANSWER 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN 113649-89-1 REGISTRY
CN Carbanilide, 4'-cyclopentyl-2-phenylthio- (6CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H24 N2 S
SR CAOLD
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS
(*File contains numerically searchable property data)
DT.CA Caplus document type: Journal
RL.NP Roles from non-patents: NORL (No role in record)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

FILE 'CAOLD' ENTERED AT 20:10:56 ON 24 JUN 2004

=> fil reg; d acc 102747-60-4; fil CAOLD

FILE 'REGISTRY' ENTERED AT 20:11:05 ON 24 JUN 2004

ANSWER 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN 102747-60-4 REGISTRY
CN Carbanilide, 4'-cyclopentyl-2-phenyl- (6CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H24 N2 O
SR CAOLD
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS
(*File contains numerically searchable property data)
DT.CA Caplus document type: Journal
RL.NP Roles from non-patents: NORL (No role in record)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

FILE 'CAOLD' ENTERED AT 20:11:06 ON 24 JUN 2004

=> fil reg; d acc 102458-17-3; fil CAOLD

FILE 'REGISTRY' ENTERED AT 20:11:20 ON 24 JUN 2004

ANSWER 1 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 102458-17-3 REGISTRY
 CN Carbanilide, 4'-cyclopentyl-2,4-dimethylthio- (6CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C20 H24 N2 S
 SR CAOLD
 LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS
 (*File contains numerically searchable property data)
 DT.CA Caplus document type: Journal
 RL.NP Roles from non-patents: NORL (No role in record)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

FILE 'CAOLD' ENTERED AT 20:11:20 ON 24 JUN 2004

=> fil reg; d acc 102016-04-6; fil CAOLD

FILE 'REGISTRY' ENTERED AT 20:11:33 ON 24 JUN 2004

ANSWER 1 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 102016-04-6 REGISTRY
 CN Carbanilide, 4-cyclopentyl- (6CI) (CA INDEX NAME)



chain nodes :

7 8 9 11

ring nodes :

1 2 3 4 5 6 13 14 15 16 17 18 19 20 21 22 24 25 26 27 28 29

chain bonds :

6-7 7-9 8-9 9-11

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 13-22 14-15 15-16 16-17 17-18 18-19 19-20
20-21 21-22 24-25 24-29 25-26 26-27 27-28 28-29

exact/norm bonds :

6-7 7-9 8-9 9-11

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 13-22 14-15 15-16 16-17 17-18 18-19 19-20
20-21 21-22 24-25 24-29 25-26 26-27 27-28 28-29



isolated ring systems :

containing 1 : 13 : 24 :

G1:O,S

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 11:CLASS
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom
23:CLASS 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom



chain nodes :

7 8 9 11

ring nodes :

1 2 3 4 5 6 13 14 15 16 17 18 19 20 21 22 24 25 26 27 28 29

chain bonds :

6-7 7-9 8-9 9-11 20-26

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 13-22 14-15 15-16 16-17 17-18 18-19 19-20
20-21 21-22 24-25 24-29 25-26 26-27 27-28 28-29

exact/norm bonds :

6-7 7-9 8-9 9-11 24-25 24-29 25-26 26-27 27-28 28-29

exact bonds :

20-26

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 13-22 14-15 15-16 16-17 17-18 18-19 19-20
20-21 21-22

isolated ring systems :

containing 1 : 13 : 24 :

G1:O,S

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 11:CLASS
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom
23:CLASS 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
 NEWS 2 "Ask CAS" for self-help around the clock
 NEWS 3 May 10 PROUSDDR now available on STN
 NEWS 4 May 19 PROUSDDR: One FREE connect hour, per account, in both May
 and June 2004
 NEWS 5 May 12 EXTEND option available in structure searching
 NEWS 6 May 12 Polymer links for the POLYLINK command completed in REGISTRY
 NEWS 7 May 17 FRFULL now available on STN
 NEWS 8 May 27 New UPM (Update Code Maximum) field for more efficient patent
 SDIs in CAPlus
 NEWS 9 May 27 CAPlus super roles and document types searchable in REGISTRY
 NEWS 10 May 27 Explore APOLLIT with free connect time in June 2004
 NEWS 11 Jun 22 STN Patent Forums to be held July 19-22, 2004

NEWS EXPRESS MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT
 MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
 AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
 NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS INTER General Internet Information
 NEWS LOGIN Welcome Banner and News Items
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
 specific topic.

All use of STN is subject to the provisions of the STN Customer
 agreement. Please note that this agreement limits use to scientific
 research. Use for software development or design or implementation
 of commercial gateways or other similar uses is prohibited and may
 result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 20:56:40 ON 24 JUN 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 20:56:55 ON 24 JUN 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 23 JUN 2004 HIGHEST RN 698346-19-9
 DICTIONARY FILE UPDATES: 23 JUN 2004 HIGHEST RN 698346-19-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

=> s l1

SAMPLE SEARCH INITIATED 21:05:16 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 112 TO ITERATE

100.0% PROCESSED 112 ITERATIONS

22 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 1606 TO 2874

PROJECTED ANSWERS: 159 TO 721

L2 22 SEA SSS SAM L1

=>


L3 STRUCTURE UPLOADED

=> d l3


L3 HAS NO ANSWERS

L3 STR

0 28 S 29




Page 1-A



Page 1-B

Page 2-A



Page 2-B

VAR G1=28/29

REP G20=(0-1) 25-24 25-26

VPA 8-12/13/14 S

NODE ATTRIBUTES:

HCOUNT	IS M1	AT	7
HCOUNT	IS M1	AT	8
NSPEC	IS R	AT	1
NSPEC	IS R	AT	2
NSPEC	IS R	AT	3
NSPEC	IS R	AT	4
NSPEC	IS R	AT	5
NSPEC	IS R	AT	6
NSPEC	IS C	AT	7
NSPEC	IS C	AT	8
NSPEC	IS C	AT	9
NSPEC	IS C	AT	10
NSPEC	IS R	AT	11
NSPEC	IS R	AT	12
NSPEC	IS R	AT	13
NSPEC	IS R	AT	14
NSPEC	IS R	AT	15
NSPEC	IS R	AT	16
NSPEC	IS R	AT	17
NSPEC	IS R	AT	18
NSPEC	IS R	AT	19
NSPEC	IS R	AT	20
NSPEC	IS R	AT	21

```

NSPEC   IS R      AT 22
NSPEC   IS R      AT 23
NSPEC   IS R      AT 24
NSPEC   IS R      AT 25
NSPEC   IS R      AT 26
NSPEC   IS R      AT 27
DEFAULT MLEVEL IS ATOM
MLEVEL   IS CLASS AT 7 8 9 28 29
DEFAULT ECLEVEL IS LIMITED

```

GRAPH ATTRIBUTES:

RSPEC I

NUMBER OF NODES IS 29

STEREO ATTRIBUTES: NONE

=> s 13

SAMPLE SEARCH INITIATED 21:07:23 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 18 TO ITERATE

100.0% PROCESSED 18 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 106 TO 614

PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L3

=> s 14 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 155.00 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

FULL SEARCH INITIATED 21:07:35 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 333 TO ITERATE

100.0% PROCESSED 333 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L5 0 SEA SSS FUL L3

=> d his

(FILE 'HOME' ENTERED AT 20:56:40 ON 24 JUN 2004)

FILE 'REGISTRY' ENTERED AT 20:56:55 ON 24 JUN 2004

L1 STRUCTURE UPLOADED

L2 22 S L1

L3 STRUCTURE UPLOADED

L4 0 S L3

L5 0 S L4 FULL

=> s 12 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 155.00 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

FULL SEARCH INITIATED 21:08:06 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 2088 TO ITERATE

100.0% PROCESSED 2088 ITERATIONS

377 ANSWERS

SEARCH TIME: 00.00.01

L6 377 SEA SSS FUL L1

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

317.98

318.19

FILE 'HCAPLUS' ENTERED AT 21:08:09 ON 24 JUN 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Jun 2004 VOL 140 ISS 26

FILE LAST UPDATED: 23 Jun 2004 (20040623/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 16

L7 28 L6

=> s 17 and cirillo, p?/au

70 CIRILLO, P?/AU

L8 8 L7 AND CIRILLO, P?/AU

=> d 18, ibib abs fhitr, 1-8

L8 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Citing
Text References

ACCESSION NUMBER: 2003:319714 HCAPLUS

DOCUMENT NUMBER: 138:338157

TITLE: Preparation of 1,4-disubstituted benzo-fused ureas as cytokine inhibitors

INVENTOR(S): Cirillo, Pier F.; Hammach, Abdelhakim; Regan, John R.

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 100 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003032989	A1	20030424	WO 2002-US32809	20021011

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003162968 A1 20030828 US 2002-269173 20021011
 PRIORITY APPLN. INFO.: US 2001-330254P P 20011018
 OTHER SOURCE(S): MARPAT 138:338157
 GI

no

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; ring A = fused (un)satd. ring contg. 3-5 carbon atoms (wherein ring A or the Ph ring to which it is fused is optionally substituted); G = (un)substituted 5-membered heteroaryl; Q = (un)substituted naphthyl, benzocyclobutanyl, indanyl, etc.; X = O, S] which are active as anti-inflammatory agents, were prepd.. Thus, reacting the carbamate II with the amine III (multi-step prepn. given) in DMSO afforded 84% urea IV. The preferred compds. I including those from the synthetic examples were evaluated for their inhibition of TNF α prodn. in THP cells, and showed IC₅₀ < 10 μ M.


IT **515843-57-9P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 1,4-disubstituted benzo-fused ureas as cytokine inhibitors)

RN **515843-57-9** HCAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[3-(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-6-yl]-1-naphthalenyl]- (9CI)
 (CA INDEX NAME)



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
--------------	----------------------

ACCESSION NUMBER: 2002:927403 HCAPLUS
 DOCUMENT NUMBER: 138:14065
 TITLE: Carbamate and oxamide compounds as inhibitors of cytokine production
 INVENTOR(S): **Cirillo, Pier F.**; Kamhi, Victor; Regan, John
 Robinson; Tsang, Michele
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA;
 Raymond, Robert, P.
 SOURCE: PCT Int. Appl., 109 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096876	A1	20021205	WO 2002-US14400	20020508
W: AE, AU, BG, BR, CA, CN, CO, CZ, EC, EE, HR, HU, ID, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1395561	A1	20040310	EP 2002-731697	20020508
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR				
US 2003092702	A1	20030515	US 2002-147675	20020517
US 6743788	B2	20040601		
PRIORITY APPLN. INFO.:			US 2001-293600P	P 20010525
			WO 2002-US14400	W 20020508

OTHER SOURCE(S): MARPAT 138:14065
 GI



AB GEC(:W)NHArXYZ [G = (un)substituted heterocyclic; E = O, NH, S; W = O, S; Ar = (un)substituted Ph, naphthyl, indenyl, heterocyclic; X = (un)substituted cycloalkyl, cycloalkenyl, aryl, heterocyclic; Y = bond, (un)substituted alkylene, alkenylene, oxaalkylene, azaalkylene, thiaalkylene; Z = (un)substituted aryl, heteroaryl, NH₂, OH, halogen, CN] were prepd. for treating cytokine mediated diseases or conditions such as chronic inflammatory diseases. Thus, 4-Me₃CC₆H₄OMe was dinitrated, reduced to the monoamine, converted to the nitro isocyanate, treated with MeOCH₂CH₂OH, and reduced to 2-methoxyethoxy N-(3-amino-5-tert.-butyl-2-methoxyphenyl)carbamate (I). 3-Bromoaniline was cyclized with (BrCH₂CH₂)₂O, converted to the tributylstannane, and coupled with 1-amino-4-bromonaphthalene to give 1-amino-4-(3-

morpholinophenyl)naphthalene which was N-protected with Cl₃CCH₂O₂CCl and treated with I to give the carbamate II. Title compds. had IC₅₀ for inhibition of TNF α < 10 μ M.


IT **477699-48-2P**

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(carbamates and oxamides as inhibitors of cytokine prodn.)

RN **477699-48-2** HCAPLUS


CN Carbamic acid, [5-(1,1-dimethylethyl)-2-methoxy-3-[[[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]amino]carbonyl]amino]phenyl]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



NO

PAGE 2-A



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text Citing References


ACCESSION NUMBER: 2002:888719 HCAPLUS
DOCUMENT NUMBER: 137:384854
TITLE: Preparation of diaryl ureas as antiinflammatory agents
INVENTOR(S): Cirillo, Pier F.; Goldberg, Daniel R.; Hammach, Abdelhakim; Moss, Neil; Regan, John Robinson
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092576	A1	20021121	WO 2002-US14733	20020508
W: AE, AU, BG, BR, CA, CN, CO, CZ, EC, EE, HR, HU, ID, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1392661	A1	20040303	EP 2002-734324	20020508
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR				
US 2003008868	A1	20030109	US 2002-143322	20020510
PRIORITY APPLN. INFO.:			US 2001-291425P	P 20010516
			WO 2002-US14733	W 20020508

GI



AB The title diaryl ureas, useful in pharmaceutic compns. for treating a cytokine mediated diseases or conditions involving inflammation such as chronic inflammatory diseases, were prepd. Thus, treating 4-(2-chloropyrimidin-4-yloxy)naphthalen-1-ylamine with Et₃N in DMF followed by addn. of Et₄NCN, and treatment of the resulting nitrile with phosgene, and reacting the intermediate with 5-tert-butyl-o-anisidine afforded the urea I.

IT **473271-86-2P**


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of diaryl ureas as antiinflammatory agents)


RN 473271-86-2 HCAPLUS

CN Methanesulfonamide, N-[5-(1,1-dimethylethyl)-2-methoxy-3-[[[4-[[2-[(2-pyridinylmethyl)amino]-4-pyrimidinyl]oxy]-1-naphthalenyl]amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




L8 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 2002:814102 HCAPLUS
 DOCUMENT NUMBER: 137:325421
 TITLE: Preparation of morpholine-containing aromatic and heteroaromatic ureas as inhibitors of inflammatory cytokines useful as anti-inflammatory agents
 INVENTOR(S): Breitfelder, Steffen; Cirillo, Pier F.; Regan, John R.
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 120 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083642	A1	20021024	WO 2001-US12253	20010413
W: AE, AU, BG, CA, CN, CO, CZ, EE, HR, HU, ID, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1381594	A1	20040121	EP 2001-927024	20010413
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR				

PRIORITY APPLN. INFO.: WO 2001-US12253 W 20010413
 OTHER SOURCE(S): CASREACT 137:325421; MARPAT 137:325421
 GI



AB Disclosed are novel arom. compds. (G-E-C(:W)-NH-Ar-X-Y-Z; e.g. 1-[5-tert-butyl-3-(2-dimethylamino-3,4-dioxocyclobut-1-enylamino)-2-methoxyphenyl]-3-[4-(6-morpholin-4-ylmethylpyridin-3-yl)naphthalen-1-yl]urea (shown as I)) wherein G, E, W, Ar, X, Y and Z are defined in the claims. The compds. are useful for treating diseases or pathol. conditions involving inflammation, such as chronic inflammatory diseases. Also disclosed are pharmaceutical compns. contg. and processes of making such compds. Tests of preferred claimed compds. for inhibition of tumor necrosis factor (TNF α) prodn. in lipopolysaccharide stimulated THP cells showed IC₅₀ < 10 μ M. Sixteen example prepn. of intermediates and claimed compds. are provided. For example, to prep. I, 5-tert-butyl-2-methoxy-1,3-dinitrobenzene was added to EtOH under N₂ purge and to this mixt., ammonium formate was added, followed by 10% Pd on C. To a soln. of the formed diamine in anhyd. MeOH at 0-5° was added 3,4-dimethoxycyclobutene-1,2-dione. To a soln. of the formed intermediate in THF at 0-5° was added dimethylamine in THF. To a mixt. of this intermediate in CH₂Cl₂ and satd. aq. NaHCO₃ at 0-5° was added phosgene in toluene followed by 1-amino-4-(6-morpholin-4-ylmethylpyridin-3-yl)naphthalene in anhyd. THF to give I.

IT **294850-71-8P**, N-Methanesulfonyl-N-[5-tert-Butyl-2-methoxy-3-[3-[4-(6-[(morpholin-4-yl)methyl]pyridin-3-yl)naphthalen-1-yl]ureido]phenyl]methanesulfonamide


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of morpholine-contg. arom. and heteroarom. ureas as inhibitors of inflammatory cytokines useful as anti-inflammatory agents)


RN **294850-71-8** HCAPLUS

CN Methanesulfonamide, N-[5-(1,1-dimethylethyl)-2-methoxy-3-[[[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]amino]carbonyl]amino]phenyl]-N-(methylsulfonyl)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 2002:814091 HCAPLUS
DOCUMENT NUMBER: 137:310705
TITLE: Preparation of 1,4-disubstituted benzo-fused arylureas for chronic inflammatory diseases
INVENTOR(S): **Cirillo, Pier F.**; Goldberg, Daniel R.; Hammach, Abdelhakim; Moss, Neil; Mueller, Kristen; Regan, John Robinson
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 155 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083628	A1	20021024	WO 2002-US8504	20020321
W: AE, AU, BG, BR, BY, CA, CN, CO, CZ, EC, EE, HR, HU, ID, IL, IN, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, UA, UZ,				

VN, YU, ZA
 RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE, TR
 EP 1381592 A1 20040121 EP 2002-723527 20020321
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, CY, TR
 US 2003083333 A1 20030501 US 2002-120028 20020410
 PRIORITY APPLN. INFO.: US 2001-283642P P 20010413
 WO 2002-US8504 W 20020321
 OTHER SOURCE(S): CASREACT 137:310705; MARPAT 137:310705
 GI

ND

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = fused (un)satd. (un)substituted ring contg. 3-5 C atoms; G = Ph, naphthyl, benzocyclobutanyl, dihydronaphthyl, etc.; L = O, NH, CO, CS, etc.; Q = Ph, naphthyl, pyridinyl, pyrimidinyl, etc.; Y (covalently attached to Q) = O, CO, NH, CONH, etc.; n = 0-2; X = O, S] were prepd. For instance, 4-amino-1-naphthol•HCl was converted to the N-Boc deriv. and alkylated with 4-(2-chloroethyl)morpholine•HCl (CH₃CN, K₂CO₃, 80°, 3 h); the product was deprotected to give 4-[2-(morpholin-4-yl)ethoxy]naphth-1-ylamine. This intermediate was reacted with phosgene (CH₂Cl₂/H₂O/NaHCO₃, 0°) and the resulting intermediate coupled to 5-tert-butyl-3-methylcarbamoyl-2-methoxyaniline (prepn. given) to afford II. I are useful in pharmaceutic compns. for treating, e.g., rheumatoid arthritis, osteoarthritis, Crohn's disease, etc.


IT **473269-78-2P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of 1,4-disubstituted benzo-fused arylureas for chronic inflammatory diseases)


RN 473269-78-2 HCAPLUS

CN 2-Pyridinecarboxylic acid, 4-[[4-[[[5-(1,1-dimethylethyl)-2-methoxy-3-[(methylsulfonyl)amino]phenyl]amino]carbonyl]amino]-1-naphthalenyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text Citing References

ACCESSION NUMBER: 2002:185696 HCAPLUS
 DOCUMENT NUMBER: 136:247592
 TITLE: Preparation of heterocyclyl arylamides and ureas as antiinflammatory agents
 INVENTOR(S): Breitfelder, Steffen; **Cirillo, Pier F.**; Regan, John R.
 PATENT ASSIGNEE(S): Germany
 SOURCE: U.S. Pat. Appl. Publ., 36 pp., Cont.-in-part of U.S. Ser. No. 505,582.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002032195	A1	20020314	US 2001-834797	20010413
US 6608052	B2	20030819		
US 6358945	B1	20020319	US 2000-505582	20000216
US 2002055507	A1	20020509	US 2001-962709	20010925
US 6660732	B2	20031209		
US 2002082256	A1	20020627	US 2001-962057	20010925
US 6656933	B2	20031202		

Handwritten notes: "no" with arrows pointing to US 2002032195 and US 6608052; "yes" with an arrow pointing to US 2002082256; "date gone" with an arrow pointing to the DATE column header.

US 2003065034 A1 20030403 US 2002-264689 20021004
 US 6703525 -nb B2 20040309
 US 2003225077 -nb A1 20031204 US 2003-424613 20030428
 US 2004019038 A1 20040129 US 2003-624289 20030721
 PRIORITY APPLN. INFO. :nb
 US 2000-505582 A2 20000216
 US 1999-124148P P 19990312
 US 1999-165867P P 19991116
 US 2001-834797 A2 20010413
 US 2001-962057 A1 20010925
 US 2001-962709 A3 20010925

OTHER SOURCE(S): MARPAT 136:247592

AB GEC(:W)NHArXYZ [E = O, NH, S; G = (substituted) Ph, naphthyl, benzocyclobutyl, dihydronaphthyl, benzocycloheptyl, indanyl, indenyl, pyridyl, quinolinyl, oxetanyl, pyrrolidinyl, piperidinyl, etc.; Ar = (substituted) Ph, naphthyl, quinolinyl, isoquinolinyl, tetrahydronaphthyl, benzofuryl, benzothienyl, benzimidazolyl, indanyl, etc.; X = (substituted) cycloalkyl, cycloalkenyl, aryl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, pyridinyl, etc.; Y = bond, (substituted) (O-, S-, SO-, SO2-, N-interrupted) alkylene; Z = (substituted) pyridinyl, piperazinyl, pyrimidinyl, pyrazinyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furyl, thienyl, etc.; W = O, S], were prepd. Thus, 5-tert-butyl-2-methoxy-1,3-dinitrobenzene (prepn. given) was stirred with ammonium formate and Pd/C in EtOH followed by 3 h reflux to give 90% diamine, which in MeOH was treated with 3,4-dimethoxycyclobutene-1,2-dione at 0-5° followed by stirring and warming to room temp. to give an intermediate. The intermediate in THF was treated with Me2NH at 0-5° followed by stirring and warming to room temp. to give the dimethylamino intermediate. The latter in CH2Cl2 was treated with COCl2 in PhMe and aq. NaHCO3 followed by removal of most volatiles. The residue was added to 1-amino-4-(6-morpholin-4-ylmethylpyridin-3-yl)naphthalene (prepn. given) in THF followed by stirring overnight to give 1-[5-tert-butyl-3-(2-dimethylamino-3,4-dioxocyclobut-1-enylamino)-2-methoxyphenyl]-3-[4-(6-morpholin-4-ylmethylpyridin-3-yl)naphthalen-1-yl]urea. Preferred title compds. inhibited TNF α prodn. in THP cells with IC50<10 μ M.

IT 294850-71-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heterocyclyl arylamides and ureas as antiinflammatory agents)


RN 294850-71-8 HCAPLUS

CN Methanesulfonamide, N-[5-(1,1-dimethylethyl)-2-methoxy-3-[[[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]amino]carbonyl]amino]phenyl]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L8 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 2001:380570 HCAPLUS
 DOCUMENT NUMBER: 135:5453
 TITLE: Preparation of aromatic heterocyclic substituted urea derivatives as non-steroidal anti-inflammatory agents
 INVENTOR(S): Breitfelder, Steffen; **Cirillo, Pier F.**; Hao, Ming-Hong; Hickey, Eugene R.; Sharma, Rajiv; Sun, Sanxing; Takahashi, Hidenori
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 88 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001036403	A1	20010525	WO 2000-US31582	20001116
W: AE, AU, BG, BR, BY, CA, CN, CZ, EE, HR, HU, ID, IL, IN, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, UZ, VN, YU, ZA RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,				

PT, SE, TR

EP 1232150 A1 20020821 EP 2000-978751 20001116

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, CY, TR

US 6492393 B1 20021210 US 2000-714539 20001116

JP 2003514808 T2 20030422 JP 2001-538892 20001116

US 2003125354 A1 20030703 US 2002-271301 20021015

PRIORITY APPLN. INFO:



US 1999-165903P P 19991116

US 2000-714539 A3 20001116

WO 2000-US31582 W 20001116

OTHER SOURCE(S): MARPAT 135:5453

GI



AB Title compds. (I) [wherein G = (un)substituted (non)arom. carbocycle or heterocycle; Ar = (un)substituted Ph, (tetrahydro)naphthyl, (tetrahydro)quinolinyl, (tetrahydro)isoquinolinyl, (dihydro)benzofuranyl, dihydrobenzothienyl, indolenyl, benzothiophenyl, benzimidazolyl, indanyl, indenyl, or indolyl; L = (un)substituted (un)satd. C chain with one or more methylene groups optionally independently replaced by O, N, or S(O)m; Q = (un)substituted Ph, naphthyl, pyridinyl, pyrimidinyl, pyridazinyl, (benz)imidazolyl, furanyl, thenyl, pyranyl, etc.; m = 0-2; X = O or S] were prep'd. as cytokine prodn. inhibitors for use as non-steroidal anti-inflammatory agents. Thus, 4-[2-(morpholin-4-yl)ethoxy]naphth-1-ylamine was treated sequentially with phosgene and 5-tert-butyl-2-methylaniline in CH₂Cl₂ to give II (42%). In a cytokine prodn. inhibition assay, II inhibited TNF α in lipopolysaccharide stimulated THP cells with IC₅₀ < 10 μ M.


IT **340825-40-3P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of arom. heterocyclic substituted urea derivs. as cytokine inhibitors for use as non-steroidal anti-inflammatory agents)

RN 340825-40-3 HCAPLUS

CN Urea, N-[4-[(2-amino-4-pyridinyl)oxy]-1-naphthalenyl]-N'-[5-(1,1-dimethylethyl)-2-methylphenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 2000:666713 HCAPLUS
DOCUMENT NUMBER: 133:252426
TITLE: Preparation of aromatic heterocyclic ureas as antiinflammatory agents
INVENTOR(S): Betageri, Rajashehar; Breitfelder, Steffen; **Cirillo, Pier F.**; Gilmore, Thomas A.; Hickey, Eugene R.; Kirrane, Thomas M.; Moriak, Monica H.; Moss, Neil; Patel, Usha R.; Proudfoot, John R.; Regan, John R.; Sharma, Rajiv; Sun, Sanxing; Swinamer, Alan D.; Takahashi, Hidenori
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 282 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 2000055139</u>	A2	20000921	<u>WO 2000-US3865</u>	20000216
<u>WO 2000055139</u>	A3	20010426		
W: AE, AU, BG, BR, BY, CA, CN, CZ, EE, HR, HU, ID, IL, IN, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, UZ, VN, YU, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
<u>EP 1165516</u>	A2	20020102	<u>EP 2000-907295</u>	20000216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
<u>BR 2000008922</u>	A	20020115	<u>BR 2000-8922</u>	20000216
<u>TR 200102817</u>	T2	20020521	<u>TR 2001-200102817</u>	20000216
<u>JP 2002539198</u>	T2	20021119	<u>JP 2000-605569</u>	20000216
<u>EE 200100483</u>	A	20021216	<u>EE 2001-483</u>	20000216
<u>NZ 514711</u>	A	20040227	<u>NZ 2000-514711</u>	20000216

AU 771273	B2	20040318	AU 2000-28817	20000216
BG 105880	A	20020531	BG 2001-105880	20010905
ZA 2001007446	A	20020910	ZA 2001-7446	20010910
HR 2001000665	A1	20030630	HR 2001-665	20010910
NO 2001004412	A	20010911	NO 2001-4412	20010911
US 2002055507	A1	20020509	US 2001-962709	20010925
US 6660732	B2	20031209		
US 2002082256	A1	20020627	US 2001-962057	20010925
US 6656933	B2	20031202		
US 2003225077	A1	20031204	US 2003-424613	20030428
US 2004019038	A1	20040129	US 2003-624289	20030721
PRIORITY APPLN. INFO :			US 1999-124148P	P 19990312
			US 1999-165867P	P 19991116
			US 2000-505582	A3 20000216
			WO 2000-US3865	W 20000216
			US 2001-962057	A1 20010925
			US 2001-962709	A3 20010925
OTHER SOURCE(S) :			MARPAT 133:252426	
GI				



II

AB The title compds. (I) [wherein Ar1 = (un)substituted pyrrole, pyrrolidine, pyrazole, imidazole, oxazole, thiazole, furan, or thiophene; Ar2 = (un)substituted Ph, (tetrahydro)naphthyl, (tetrahydro)quinoline, (tetrahydro)isoquinoline, benzimidazole, benzofuran, indanyl, indenyl, or indole; W = O or S; X = (un)substituted cycloalkyl, cycloalkenyl, Ph, furan, thiophene, pyrrole, imidazolyl, pyridine, pyrimidine, (dihydro)pyridinone, (dihydro)maleimide, piperidine, piperazine, or pyrazine; Y = a bond or (un)substituted satd. or unsatd. alkyl optionally interrupted by O, NH, S(O), SO₂, or S; Z = (un)substituted Ph, pyridine, pyrimidine, pyridazine, imidazole, (tetrahydro)furan, thiophene, (tetrahydro)pyran, 1,3-dioxolanone, 1,3-dioxanone, 1,4-dioxane, (thio)morpholine (sulfoxide), piperidine, cyclohexanone, pentamethylene sulfoxide, etc.] were prepd. for the treatment of diseases or pathol. conditions involving inflammation, such as chronic inflammatory diseases. Thus, coupling 2-cyclohexenone with 4-bromo-1-naphthylamine in the presence of Pd(PPh₃)₂Cl₂, DPPP, and NaHCO₃ in DMF, followed by conversion of the amine to an isocyanate using ClCOCl and immediate addn. of 1-(4-methylphenyl)-3-tert-butyl-1H-pyrazol-5-amine, gave the urea II. In a cytokine prodn. inhibition assay, preferred compds. of the invention

showed IC₅₀ < 10 µM against TNF-α in lipopolysaccharide stimulated THF cells.


IT **294849-72-2P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of arom. heterocyclic urea antiinflammatory agents by conversion of arylamines to isocyanates followed by addn. of heterocyclic amines)


RN **294849-72-2** HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)phenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



=> d his

(FILE 'HOME' ENTERED AT 20:56:40 ON 24 JUN 2004)

FILE 'REGISTRY' ENTERED AT 20:56:55 ON 24 JUN 2004

L1	STRUCTURE UPLOADED
L2	22 S L1
L3	STRUCTURE UPLOADED
L4	0 S L3
L5	0 S L4 FULL
L6	377 S L2 FULL

FILE 'HCAPLUS' ENTERED AT 21:08:09 ON 24 JUN 2004

L7	28 S L6
----	---------

L8 8 S L7 AND CIRILLO, P?/AU

=> s 17 not 18

L9 20 L7 NOT L8

=> s 19 and patel, u?/au

151 PATEL, U?/AU

L10 0 L9 AND PATEL, U?/AU

=> s 19 and proudfoot, j?/au

249 PROUDFOOT, J?/AU

L11 0 L9 AND PROUDFOOT, J?/AU

=> s 19 and swinamer, a?/au

9 SWINAMER, A?/AU

L12 0 L9 AND SWINAMER, A?/AU

=> s 19 and takahashi, h?/au

12788 TAKAHASHI, H?/AU

L13 0 L9 AND TAKAHASHI, H?/AU

=> s 19 and gilmore, t?/au

151 GILMORE, T?/AU

L14 0 L9 AND GILMORE, T?/AU

=> s 19 and sharma, r?/au

5153 SHARMA, R?/AU

L15 0 L9 AND SHARMA, R?/AU

=> d 19, ibib abs fhitstr, 1-9

L9 ANSWER 1 OF 20 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
--------------	----------------------

ACCESSION NUMBER: 2004:433797 HCAPLUS

DOCUMENT NUMBER: 140:423477

TITLE: Preparation of diaryl ureas as inhibitors of p38 kinase

INVENTOR(S): Miller, Scott; Osterhout, Martin; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Gunn, David E.; Hatoum-Mokdad, Holia; Rodriguez, Marell; Sibley, Robert; Wang, Ming; Turner, Tiffany; Brennan, Catherine

PATENT ASSIGNEE(S): Bayer Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 60 pp., Cont. of U.S. Ser. No. 458,015, abandoned.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004102636	A1	20040527	US 2002-60396	20020201
<u>PRIORITY APPLN. INFO.:</u>				
			US 1997-126439P	P 19971222
			US 1998-285522	B1 19981222
			US 1999-458015	B1 19991210

AB A method of treating a p-38 mediated disease other than cancer comprises

administration of BNHCONHA [A = (substituted) Ph, pyridyl, 2-thienyl; B = (substituted) aryl, heteroaryl contg. ≥ 1 6-membered arom. structure contg. 0-4 N, O, or S atoms]. Thus, 5-tert-butyl-2-(3-tetrahydrofuranlyoxy)aniline (prepn. given) and p-tolyl isocyanate were stirred 8 h in PhMe to give 75% N-(5-tert-butyl-2-(3-tetrahydrofuranlyoxy)phenyl)-N'-(4-methylphenyl)urea. Title compds. inhibited p38 kinase with $IC_{50} = 1-10 \mu M$.


IT **228400-63-3P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of diaryl ureas as inhibitors of p38 kinase)

RN **228400-63-3** HCAPLUS

CN Urea, N-(3-methoxy-2-naphthalenyl)-N'-(4-(4-pyridinylthio)phenyl)- (9CI)
(CA INDEX NAME)




L9 ANSWER 2 OF 20 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text Citing
References

ACCESSION NUMBER: 2004:142968 HCAPLUS
DOCUMENT NUMBER: 140:193056
TITLE: Combinations of active agents with p38 MAP kinase inhibitors, pharmaceutical compositions, and use in the treatment of cytokine-mediated diseases
INVENTOR(S): Simianer, Stefan; Bilbault, Pascal; Cappola, Michael L.; Way, Susan Lynn
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA; Boehringer Ingelheim France
SOURCE: PCT Int. Appl., 168 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014387	A1	20040219	WO 2003-US25341	20030812
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ</p> <p>RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG</p>				
US 2004110755	A1	20040610	US 2003-638702	20030811
PRIORITY APPLN. INFO.:			US 2002-403115P	P 20020813

GI



AB The invention relates to pharmaceutical combination therapies based on p38 kinase inhibitors and another active ingredients, pharmaceutical compns. comprising such combinations, processes for prepg. them, and their use in the treatment of cytokine-mediated diseases. Prepn. of I (BIRB 796 BS) is described.


IT **294849-84-6**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combinations of active agents with p38 MAP kinase inhibitors, pharmaceutical compns., and use in treatment of cytokine-mediated diseases)


RN **294849-84-6** HCAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 20 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 2004:142601 HCAPLUS
DOCUMENT NUMBER: 140:193063
TITLE: Anticoagulant and fibrinolytic therapy using p38 MAP kinase inhibitors
INVENTOR(S): Wood, Chester C.; Van Der Poll, Tom
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., Germany; Boehringer Ingelheim Pharma GmbH & Co. KG
SOURCE: U.S. Pat. Appl. Publ., 47 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004033222	A1	20040219	US 2003-630599	20030730
WO 2004016267	A1	20040226	WO 2003-US23841	20030730

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-403422P P 20020814

AB Disclosed are methods for a treating a disease or condition relating to blood coagulation and fibrinolysis using p38 MAP kinase inhibitors. 1-(3-Tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea, prepn. given, was tested in humans.


IT 294849-84-6

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (as p38 MAP kinase inhibitor; anticoagulant and fibrinolytic therapy with p38 MAP kinase inhibitors)


RN 294849-84-6 HCAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L9 ANSWER 4 OF 20 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 2004:41274 HCAPLUS
 DOCUMENT NUMBER: 140:99644
 TITLE: Pharmaceutical compositions based on novel anticholinergics and p38 kinase inhibitors
 INVENTOR(S): Pairret, Michel; Meade, Christopher John Montague; Pieper, Michael P.
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany
 SOURCE: PCT Int. Appl., 190 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004725	A2	20040115	WO 2003-EP6739	20030626
WO 2004004725	A3	20040527		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG

US 2004044020 A1 20040304 US 2003-611717 20030701
PRIORITY APPLN. INFO.: EP 2002-15231 A 20020709
US 2002-407733P P 20020903
OTHER SOURCE(S): MARPAT 140:99644
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to novel pharmaceutical compns. based on novel anticholinergics and p38 kinase inhibitors, processes for prepg. them and their use in the treatment of respiratory diseases. Inhalation powders were prepd. contg. anticholinergic I and p38 kinase inhibitor II.


IT **294849-84-6**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. based on novel anticholinergics and p38 kinase inhibitors)


RN 294849-84-6 HCAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



Full Text	Citing References
--------------	----------------------

ACCESSION NUMBER: 2003:818257 HCAPLUS
 DOCUMENT NUMBER: 139:312451
 TITLE: Inhalant p38 kinase inhibitor formulations for treating mucus hypersecretion
 INVENTOR(S): Jung, Birgit
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany
 SOURCE: PCT Int. Appl., 191 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003084503	A2	20031016	WO 2003-EP3434	20030402
WO 2003084503	A3	20040408		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003220336	A1	20031127	US 2003-400421	20030327
PRIORITY APPLN. INFO.:			EP 2002-7699	A 20020405
			US 2002-385856P	P 20020605
OTHER SOURCE(S):		MARPAT 139:312451		
GI				




AB The invention relates to the use of p38 kinase inhibitors for the prepn. of a pharmaceutical compn. suitable for inhalation for the treatment of mucus hypersecretion. Furthermore the invention is directed to pharmaceutical compns. suitable for inhalation comprising p38 kinase inhibitors such as I and methods for their prepn.

IT **294849-84-6**


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (inhalant p38 kinase inhibitor formulations for treating mucus hypersecretion)

RN 294849-84-6 HCAPLUS
 CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L9 ANSWER 6 OF 20 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text Citing
 Text References

ACCESSION NUMBER: 2003:656575 HCAPLUS
 DOCUMENT NUMBER: 139:197476
 TITLE: Preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity
 INVENTOR(S): Dumas, Jacques; Scott, William J.; Elting, James; Hatoum-Makdad, Holia
 PATENT ASSIGNEE(S): Bayer Corporation, USA
 SOURCE: PCT Int. Appl., 142 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068223	A1	20030821	WO 2003-US4102	20030211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				

PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
 UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
 NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML,
 MR, NE, SN, TD, TG

US 2004023961

A1

20040205

US 2003-361844

20030211


PRIORITY APPLN. INFO.:

US 2002-354948P

P

20020211

GI



AB 283 Of the title ureas useful for treating diseases mediated by raf kinase and diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes, were claimed. Synthesis of 6 ureas such as I was described. Thus, reacting 3-(tert-butyl)-1-(4-methylphenyl)pyrazole-5-ylamine with 4-(2-morpholin-4-ylethoxy)naphthylamine (prepns. given) and CDI in CH₂Cl₂ afforded 80% I which showed IC₅₀ of < 1 μM in in vitro raf kinase and in in vitro Flk-1 ELISA assay.

IT **294849-72-2P**


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)


RN 294849-72-2 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)phenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT:

17

THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 20 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
--------------	----------------------

ACCESSION NUMBER: 2003:221509 HCAPLUS

DOCUMENT NUMBER: 138:231790

TITLE: Methods using aromatic heterocyclyl compounds for
treating cytokine-mediated diseases

INVENTOR(S): Moss, Neil; Regan, John R.

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 175 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022273	A1	20030320	WO 2002-US28615	20020909
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,			

PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG

US 2003060455 A1 20030327 US 2002-237306 20020909

EP 1427412 A1 20040616 EP 2002-797884 20020909

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

PRIORITY APPLN. INFO.:

US 2001-318958P P 20010913

WO 2002-US28615 W 20020909

OTHER SOURCE(S): MARPAT 138:231790

AB Methods are disclosed for treating acute and chronic inflammation in the lung caused by inhalation of smoke, endometriosis, Behcet's disease, uveitis, ankylosing spondylitis, pancreatitis, cancer, Lyme disease, sepsis, chronic obstructive pulmonary disease, traumatic arthritis, congestive heart failure and restenosis percutaneous transluminal coronary angioplasty, known to be cytokine mediated, using arom. heterocyclic compds. described in WO 00/55139.

IT **294850-09-2**


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(arom. heterocyclcyl compds. for treating cytokine-mediated diseases)


RN 294850-09-2 HCAPLUS

CN Urea, N-[3-(2,3-dihydroxypropyl)-5-(1,1-dimethylethyl)-2-hydroxyphenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 8 OF 20 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
--------------	----------------------

ACCESSION NUMBER: 2000:98559 HCAPLUS
 DOCUMENT NUMBER: 132:137410
 TITLE: Preparation of novel azabicyclic compounds for treatment of CNS disorders
 INVENTOR(S): Gaster, Laramie Mary; Heightman, Thomas Daniel; Wyman, Paul Adrian
 PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK
 SOURCE: PCT Int. Appl., 40 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000006575	A2	20000210	WO 1999-EP5350	19990723
WO 2000006575	A3	20000518		

W: CA, JP, US

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRIORITY APPLN. INFO.:	GB 1998-16288	A	19980728
	GB 1998-27881	A	19981217

OTHER SOURCE(S): MARPAT 132:137410
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; Ra = II-IV (wherein P1-P3 = Ph, bicyclic aryl, 5-7 membered heterocyclyl, etc.; R1 = H, halo, alkyl, etc.; R2-R3 = halo, alkyl, cycloalkyl, etc.; a, b = 0-2; A = a bond, O, CH2, etc.; E = (un)substituted 5-7 membered carbocyclic ring fused at the 2,3- or 3,4-positions of the adjacent Ph ring, the ring E optionally fused to a further (un)substituted Ph ring); L = C(:V)DG, DGC(:V), YC(:V)DG; V = O, S; Y = NH, N(alkyl), CH2, O; D = N, C, CH; G = H, alkyl; Rb1, Rb2 = H, halo, OH, etc.; R4 = (un)substituted V (X = N, CH, C; m = 1-3), VI], useful in the treatment of CNS disorders such as depression, were prepd. Thus, treatment of 4-(pyridin-4-yl)naphth-1-ylamine with triphosgene in the presence of Et3N in DCM followed by addn. of (S)-4-methoxy-3-(octahydropyrrolo[1,2-a]pyrazin-2-yl)aniline in DCM afforded 91% (S)-VII. All presented examples of compds. I had pKi > 7.4 at 5-HT1A, 5-HT1B and 5-HT1D receptors.


IT 256923-80-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of novel azabicyclic compds. for treatment of CNS disorders)

RN 256923-80-5 HCAPLUS

CN Urea, N-[3-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-4-methoxyphenyl]-N'-[4-(4-pyridinyl)-1-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 9 OF 20 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text Citing
References

ACCESSION NUMBER: 1999:421667 HCAPLUS
DOCUMENT NUMBER: 131:58659
TITLE: Preparation of diaryl ureas as inhibitors of p38 kinase.
INVENTOR(S): Miller, Scott; Osterhout, Martin; Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Gunn, David; Hatoum-Mokdad, Holia; Rodriguez, Mareli; Sibley, Robert; Wang, Ming
PATENT ASSIGNEE(S): Bayer Corporation, USA
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932463	A1	19990701	WO 1998-US27265	19981222
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2315715	AA	19990701	CA 1998-2315715	19981222
AU 9919399	A1	19990712	AU 1999-19399	19981222
EP 1042305	A1	20001011	EP 1998-964221	19981222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001526276	T2	20011218	JP 2000-525400	19981222
PRIORITY APPLN. INFO.: US 1997-995749 A 19971222				
WO 1998-US27265 W 19981222				

OTHER SOURCE(S): MARPAT 131:58659
AB A method of treating a p-38 mediated disease other than cancer comprises administration of BNHCONHA [A = (substituted) Ph, pyridyl, 2-thienyl; B = (substituted) aryl, heteroaryl contg. ≥1 6-membered arom. structure contg. 0-4 N, O, or S atoms]. Thus, 5-tert-butyl-2-(3-


tetrahydrofuranyloxy)aniline (prepn. given) and p-tolyl isocyanate were stirred 8 h in PhMe to give 75% N-(5-tert-butyl-2-(3-tetrahydrofuranyloxy)phenyl)-N'-(4-methylphenyl)urea. Title compds. inhibited p38 kinase with IC50 = 1-10 µM.

IT **228400-63-3P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of diaryl ureas as inhibitors of p38 kinase)

RN 228400-63-3 HCAPLUS

CN Urea, N-(3-methoxy-2-naphthalenyl)-N'-[4-(4-pyridinylthio)phenyl]- (9CI)
(CA INDEX NAME)



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file caold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

125.69

443.88

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-11.78

-11.78

FILE 'CAOLD' ENTERED AT 21:19:24 ON 24 JUN 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d his

(FILE 'HOME' ENTERED AT 20:56:40 ON 24 JUN 2004)

FILE 'REGISTRY' ENTERED AT 20:56:55 ON 24 JUN 2004

L1 STRUCTURE UPLOADED

L2 22 S L1

• L3 STRUCTURE UPLOADED
 L4 0 S L3
 L5 0 S L4 FULL
 L6 377 S L2 FULL

FILE 'HCAPLUS' ENTERED AT 21:08:09 ON 24 JUN 2004

L7 28 S L6
 L8 8 S L7 AND CIRILLO, P?/AU
 L9 20 S L7 NOT L8
 L10 0 S L9 AND PATEL, U?/AU
 L11 0 S L9 AND PROUDFOOT, J?/AU
 L12 0 S L9 AND SWINAMER, A?/AU
 L13 0 S L9 AND TAKAHASHI, H?/AU
 L14 0 S L9 AND GILMORE, T?/AU
 L15 0 S L9 AND SHARMA, R?/AU

FILE 'CAOLD' ENTERED AT 21:19:24 ON 24 JUN 2004

=> s 16

L16 2 L6

=> d 116, all, 1-2

L16 ANSWER 1 OF 2 CAOLD COPYRIGHT 2004 ACS on STN
 AN CA59:13238e CAOLD
 TI hydrazides - (XVII) hydrazones and thioureas with antituberculous activity
 AU Budeanu, Constantin H.; Budeanu, E.; Gaiginschi, A.; Radu C.
 IT 52540-96-2 88513-18-2 92160-05-9 92160-56-0 93535-33-2 94461-81-1
95942-51-1 98396-42-0 100027-18-7 100150-24-1 100259-97-0 100265-63-2
100660-40-0 101015-77-4 **101201-07-4**


L16 ANSWER 2 OF 2 CAOLD COPYRIGHT 2004 ACS on STN
 AN CA59:5124e CAOLD
 TI hydrazides - (XIV) derivs. of isonicotinoyl hydrazide, (XV) thiourea
 derived from the isonicotinoylhydrazone of p-aminoacetophenone
 AU Budeanu, Constantin H.
 IT 895-82-9 4456-77-3 26051-66-1 52540-96-2 91642-09-0 92160-05-9
92160-56-0 92193-14-1 93535-33-2 95942-51-1 98396-42-0 100027-18-7
100150-24-1 100259-97-0 100265-63-2 100660-40-0 101015-77-4 **101201-07-4**

=> fil reg; d acc 101201-07-4; fil CAOLD


FILE 'REGISTRY' ENTERED AT 21:19:38 ON 24 JUN 2004

ANSWER 1 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 101201-07-4 REGISTRY
 CN Isonicotinic acid, [α -methyl-p-[3-(1-naphthyl)-2-thioureido]benzylidene]hydrazide (7CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C25 H21 N5 O S
 SR CAOLD
 LC STN Files: CA, CAOLD, CAPLUS
 DT.CA Caplus document type: Journal
 RL.NP Roles from non-patents: NORL (No role in record)

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

FILE 'CAOLD' ENTERED AT 21:19:39 ON 24 JUN 2004

=>